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Abstract 
 Coronaviruses are a family of positive-sense, single-stranded, 5’-capped and 3’-
polyadenylated RNA viruses that replicate entirely in the cell cytoplasm.  Replication of the viral 
genome requires translation to produce proteins used for RNA synthesis and virion assembly.  
The 5’- and 3’- untranslated regions of the coronavirus genome have been found to contain cis-
acting elements that are required for replication of the genome and a defective interfering RNA.  
Presumably, both viral and cellular proteins interact with these elements and serve as trans-
acting factors in genome translation and replication.  Of interest is the functional significance of 
a 5’-proximal cis-acting 397-nucleotide region which includes the 210-nucleotide 5’ untranslated 
regions and the 5’ proximal 187 nucleotides of the coding region for the first nonstructural 
protein, p28. 
 Here, research examining the structural requirements in this region and in the 3’ 
untranslated region for bovine coronavirus replication is presented.  The following features were 
discovered:  (i) A second higher order structure within the coding region of p28 is required for 
replication but not translation of the defective interfering RNA.  Although no viral proteins were 
found to bind this region, two cellular proteins of ~60 and ~100kDa were found which might 
prove to be essential trans-acting factors.  (ii) p28, the first synthesized protein in the genome is 
an RNA binding protein that interacts with cis-replication stem-loops in the 5’ and 3’ untranslated 
regions.  p28 may therefore function through these interactions to regulate genome translation 
or replication.  (iii)  In constructs with a renilla luciferase reporter containing only the genomic 5’ 
and 3’ untranslated regions, in vitro translation in the absence of viral proteins revealed a 5’ and 
3’ end interaction that mediates a repression of cap-dependent translation.  Therefore, 
translation of the coronavirus genome may require the assistance of viral proteins.   
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Chapter I.  Literature Review 
Background 
Coronavirus History 
 The Coronaviridae belong to the order Nidovirales and were formally characterized as a 
family around 1975 (122).  However, the viruses that make up this family were first isolated as 
early as the 1930s and new viruses continue to be isolated from birds, mammals, and humans. 
As shown in Table 1-1, coronaviruses have been categorized into three groups based on 
antigenic differences and genome sequence (106).   Group 3 includes infectious bronchitis virus 
(IBV), a significant bird pathogen, as well as other avian coronaviruses that cause respiratory 
and enteric diseases in birds (112).  Recently, the first non-avian group 3-like coronavirus was 
isolated from a beluga whale (110).   Group 1 includes both animal and human pathogens such 
as transmissible gastroenteritis virus (TGEV) and two human coronaviruses, HCoV-229E and 
HCoV NL63.  Infection with a group 1 virus typically results in acute respiratory and 
gastroenteric disease (156).  Group 2 coronaviruses are perhaps the most well studied of the 
coronaviruses partially due to the appearance of SARS in 2003 and also because both mouse 
hepatitis virus (MHV) and bovine coronavirus (BCoV) have been used as models for the study 
of coronavirus replication and pathogenesis.  Group 2 contains the majority of known human 
coronaviruses including HCoV-OC43, HCoV 4408, and HCoV HKU1, all of which have been 
associated with respiratory infections (77).  Other group 2 viruses infect animals and are of 
significant economic importance in terms of farming and agriculture and also cause both 
respiratory and gastroenteric diseases (112).   
 Recently, coronaviruses have been the subject of intense research due to the 
appearance of SARS-CoV.  The emergence of SARS in early 2003 resulted in 8,098 reported 
cases and 774 deaths (~10%) worldwide (24).  Infection most commonly resulted in severe 
pneumonia and spread via respiratory droplets (24).  Since that time the number of new 
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Table 1-1.  Coronavirus Group Members. 
Coronavirus Year Isolated Host
a Disease Gen.b Genbankc 
Group 1      
TGEV   1946  (46) Pig Gastroenteritis 28586 AJ271965 
HCoV 229E  1966  (61) Human Respiratory 27317 AF304460 
Feline CoV 1970 (163) Cat Enteritis, Peritonitis 29147 DQ010921 
Canine CoV 1974  (13) Dog Enteritis  AY796289 
PEDV 1978  (28) Pig Diarrhea 28033 AF353511 
Rabbit CoV 1980  (91) Rabbit Cardiomyopathy   
HCoV NL63                                     2004 (52, 157) Human Respiratory 27553 AY567487 
Bat CoV 2005 (126) Bat Unknown  AY864196 
Raccoon dog CoV 2007 (161) Rac. Dog Unknown  EF192157 
Group 2      
Mouse hepatitis virus 1949  (29) Mouse Enteritis, Hepatitis 31526 NC_006852 
PHEV 1962  (59) Pig Vomiting 30480 DQ011855 
Human CoV OC43 1965 (155) Human Respiratory 30738 AY391777 
Rat CoV 1970 (121) Rat Sialodacryoadenitis  AF207551 
Bovine CoV 1973 (145) Cow Diarrhea, Dysentery 31028 U00735 
Puffinosis CoV 1982 (119) Bird Unknown  AJ544718 
Equine CoV  1983   (69) Horse Diarrhea 30992 EF446615 
Human CoV 4408 1994 (174) Human Enteritis  AF523848 
Canine Respiratory CoV 2003  (50) Dog Respiratory  DQ682406 
SARS CoV                                       2003 (88, 123) Human Severe pneumonia 29751 AY274119 
Bat SARS CoV 2005  (99) Bat Unknown 29736 DQ071615 
Bat SARS HKU3 2005  (93) Bat Unknown 29728 DQ022305 
Human CoV HKU1 2005 (167) Human Respiratory 29926 AY597011 
HCoV type 5 2006     *** Human Unknown  AY860197 
Bat CoV HKU4 2006 (168) Bat Unknown 30286 EF065505 
Bat CoV HKU5 2006 (168) Bat Unknown 30482 EF065509 
Bat CoV HKU9 2007 (169) Bat Unknown 29114 EF065513 
Group 3      
IBV 1937     (9) Chicken Infectious Bronchitis 27608 M95169 
Turkey CoV 1957 (154) Turkey Gastroenteritis 27657 EU095850 
Pheasant CoV 2002  (23) Bird Respiratory  AJ619579 
Coronavirus SW1 2008  (110) Whale Unknown 31686 EU111742 
Unclassified      
Duck CoV 2005  (76) Duck Unknown  AJ854130 
Goose CoV 2005  (76) Goose Unknown  AJ854114 
Pigeon CoV 2005  (76) Pigeon Unknown  AJ854131 
Parrot CoV 2006  (57) Parrot Unknown  DQ233651 
Human CoV NO 2006   *** Human Unknown  AM261820 
Chicken enteric CoV 2006   *** Chicken Unknown  DQ401279 
Quail CoV 2007  (35) Quail Unknown  EF446155 
Asian leopard cat CoV 2007  (43) Leop. Cat Unknown  EF584908 
Chinese bamboo rat CoV 2007  (43) Rat Unknown  EF584902 
Chinese ferret badger CoV 2007  (43) Fer.Bad. Unknown  EF584914 
Flying squirrel CoV 2007  (43) Squirrel Unknown  EF584907 
Lesser Indian civet CoV 2007  (43) Civet Unknown  EF584903 
Masked palm civet CoV 2007  (43) Civet Unknown  EF584905 
Siberian weasel CoV 2007  (43) Weasel Unknown  EF584906 
Yellow-bellied weasel CoV 2007  (43) Weasel Unknown  EF584904 
TGEV, transmissible gastroenteritis virus; PEDV, porcine epidemic diarrhea virus; PHEV, porcine hemagglutinating 
encephalomyelitis virus; IBV, infectious bronchitis virus   
a host denotes animals from which virus was first isolated.   
bGenome length in nucleotides 
cGenbank numbers refer to representative sequence.  If not available, a partial sequence is given. 
  ***Unpublished sequences from Genbank.
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coronaviruses detected has more than doubled and new coronaviruses representing all three 
groups have been isolated from birds, bats, humans, and other mammals.  For many of the 
newly discovered and unclassified isolates it is not known if infection actually results in disease 
or if the virus was obtained from a reservoir host.  In all, over 20 complete genomes have been 
sequenced (Table 1-1). 
Coronavirus Replication   
 BCoV like all coronaviruses is a positive sense, single-stranded RNA virus with a 5’ cap 
and 3’ poly(A) tail.  The genome is 31kb, making it one of the largest viral RNA genomes known 
(106). Coronaviruses replicate entirely in the cytoplasm and after uncoating the genome is 
initially translated to produce viral proteins for RNA synthesis.  These replicase proteins are 
used to replicate the genome and transcribe a set of 5’ and 3’ coterminal subgenomic 
messenger RNAs (sgmRNA) which are translated to yield the structural proteins necessary for 
virion assembly and other accessory proteins (106).  In BCoV there are eight sgmRNAs (66, 
135) (Fig. 1-1).  sgmRNAs all have a common 5’ end, the viral genomic leader sequence (nts 1-
65), encoded only at the genome and added by discontinuous transcription.  The sequences of 
the 5’ UTRs are unique to each sgmRNA and for BCoV range from 70 to 193 nucleotides (nt) in 
length (135).  The genomic 3’ UTR and poly(A) tail are also present on each sgmRNA (106).    
BCoV sgmRNA 7 which encodes the nucleocapsid protein and is the most abundantly 
translated RNA species, has one of the shortest 5’ UTRs, 77nt, and contains the 65nt leader 
sequence (135).  Following replication, genomic RNA is coated to form the nucleocapsid which 
is then packaged into virus particles by budding through the endoplasmic reticulum or Golgi 
membranes.  Virions collect in vesicles that fuse with the plasma membrane via the exocytic 
pathway and are released outside the cell (51). 
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Figure 1-1.  Coronavirus Replication Scheme.  Adapted from K. Holmes and M. Lai, Fields 
Virology, 1996; Sethna, Hung, Brian. 1989. PNAS 86:5626. 
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Defective Interfering RNA (DI RNA) 
 To facilitate identification and characterization of cis-acting elements in BCoV, a defective-
interfering RNA (DI RNA) has been used.  The naturally occurring BCoV DI RNA is composed of the 
termini of the genome.  The 5’-terminal 495 nucleotides (210-nt 5’ UTR, 285-nt nsp 1) is fused in 
frame to the fourth nucleotide upstream of the nucleocapsid (N) start codon and contains the entire 
N sequence and the 288 nucleotide 3’ UTR plus a poly(A) tail (26).    To date all characterized 
coronavirus DI RNAs contain the entirety of the 5’ and 3’ UTRs and a portion of the first 
nonstructural protein coding region (14, 15).  Replication of the BCoV DI RNA presumably reflects 
replication of the genome and contains the cis-acting elements necessary for genomic replication.  
BCoV DI RNA replication is accomplished with the help of BCoV trans-acting factors (Fig. 1-2).  The 
BCoV DI RNA and sgmRNA 7, which codes for the nucleocapsid protein are almost identical in 
composition.  The difference is a 421 nucleotide region that includes 136 nucleotides of the 5’ UTR 
and part of the nsp 1 coding region.  This is interesting as sgmRNAs do not replicate, leaving the 
421 nucleotide region as the determining factor for replication.  The region that confers the ability to 
replicate includes cis-acting stem loops III and IV in the 5’ UTR, and 285 nucleotides of nsp 1, 187 of 
which are required for DI RNA replication, including cis-acting stem loop VI (15, 20) (Fig. 1-2).  
These elements are described in more detail below. 
cis-Acting Replication Elements   
 To date six cis-acting elements in the 5’ and 3’ untranslated regions (UTR) have been 
identified and shown to be required for DI RNA replication.  In the 5’ terminal 90nt region of the 
210nt 5’ UTR, two stem-loops, SLI (nt11 to 42) and SLII (nt51 to 84) were predicted to exist by 
the Tinoco algorithm and confirmed by structure probing (25, 26).  Recently in MHV, two 
different stem-loops in this same region (nt 1 to 51) were described and one of these was 
shown to be a cis-acting replication element (102).  The second cis-acting element identified in 
the 5’ UTR, SLIII (nt 97 to 116), is a conserved element in group 2 coronaviruses and has been 
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Figure 1-2.  BCoV Genome and DI RNA.  Sixteen nonstructural proteins are encoded within ORF 1a/b and structural genes 
including hemagluttin-esterase (HE) and the spike glycoprotein (S) are encoded at the 3’ terminus of the genome.  cis-Acting 
secondary structures are found in both the 5’ and 3’ UTRs.  Two cis-acting structures are also found in the 5’ terminal coding 
region of nsp 1 (SLV-VI).  The BCoV DI RNA is composed of only the termini of the genome, including the 5’ proximal cis-acting 
region, the entire nucleocapsid coding region, and the 3’ UTR.  A 30nt reporter sequence has been inserted for use in replication 
assays. 
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confirmed by RNase structure probing (129). The third and final cis-acting element identified in 
the 5’ UTR, SLIV (nt 186 to 215), is located immediately upstream of the coding region and 
contains the start codon for the ORF 1a/1b polyprotein.  This stem-loop is conserved among 
group 2 coronaviruses except for SARS-CoV (130).  Three elements within the 3’ UTR have 
been identified as cis-acting replication elements.  A bulged stem-loop and associated 
pseudoknot located just downstream of the nucleocapsid coding region, a second bulged stem-
loop located near the 3’ terminus that contains a conserved octamer sequence GGAAGAGC, 
and a poly(A) tail (55, 67, 68, 143, 166). In addition to these six elements, a seventh cis-acting 
stem-loop has been identified immediately downstream of the 5’ UTR within the coding region of 
the first nonstructural protein (nsp 1), p28 (Fig. 1-2) (20). This is the second cis-acting element 
discovered in the coding region of coronaviruses, the first being the frame-shifting pseudoknot 
located at the ORF 1a/1b junction (16, 17). Although these described higher-order elements 
have been shown to function in DI RNA replication, the exact roles they play in replication of the 
genome remain unknown.   
Translation and Proteins  
 Translation of the capped and polyadenylated viral genome and sgmRNAs is believed to 
follow the typical cellular mRNA model and occur in a closed loop or circular complex through 
interactions between the 5’ cap structure and 3’ poly(A) tail (15).  After adsorption and 
uncoating, the genomic RNA must be translated in order to produce the viral proteins that are 
necessary for RNA synthesis and replication.  In coronaviruses, the 5’ and 3’ UTRs have been 
shown to be important for replication but it is not known how or if these elements function 
specifically in translation.  In the closely related MHV, the leader sequence at the 5’ terminus 
has been described as a translational enhancer in virus infected cells and mutation of stem-loop 
II in this region decreases translation efficiency in vitro (102, 148).  In addition, the viral N 
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protein has been identified as enhancing translation of a reporter RNA in virus infected cells 
(149).  The N protein also binds to the 5’ leader sequence; however it is unclear if it functions as 
a translation enhancer through RNA-protein interactions with the leader sequence (117, 147). 
 The genomic RNA of coronaviruses is translated into a polyprotein (ORF 1a/1b) that is 
cleaved co- and post-translationally into sixteen nonstructural proteins (nsps) by two viral 
proteases (56).  The functions of a majority of the nonstructural proteins have been predicted, 
but only a few have been confirmed with experimental data.  ORF 1a contains 11 predicted 
protein end products (nsp 1-11) and ORF 1b contains five putative protein end products (nsps 
12-16), identified as an RNA-dependent RNA-polymerase (RdRp), a helicase, an exonuclease, 
an endonuclease, and a 2’-O-methyltransferase (Fig. 1-2) (34, 141).  Of the putative proteins in 
ORF 1b, function has been demonstrated for nsps 14 and 15, an exonuclease and 
endonuclease, respectively, in SARS-CoV (11, 75, 111).  In SARS-CoV ORF 1a,  nsp 8, has 
been shown to be a primase, and nsp 9 has been shown to be an RNA binding protein of 
unknown function (49, 74).  Other nonstructural proteins with known functions include nsp 3, 
which contains two papain-like protease domains and nsp 5, a 3C-like protease (106). 
 Structural and accessory proteins are encoded in the 3’ proximal one-third of the 
genome and are translated from polycistronic sgmRNAs.  Although each sgmRNA contains the 
coding sequence for downstream ORFs, and are therefore structurally polycistronic, only the 5’-
most ORF is translated, making the sgmRNAs functionally monocistronic.  All coronaviruses 
have sgmRNAs that code for the spike glycoprotein (S), envelope (E), membrane (M), and 
nucleocapsid (N) proteins.  Other ORFs code for accessory proteins that are not necessarily 
conserved among coronaviruses.  Some of those identified are group specific, such as the 
hemagglutinin-esterase (HE) which is found in some group 2 viruses (Fig. 1-2) (15).  Accessory 
proteins, many of which have unknown functions, can be structural or nonstructural proteins 
(106). 
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Identified Protein Factors  
 To facilitate virus replication, both viral and cellular proteins interact with viral RNA and 
cis-acting RNA elements.  In coronaviruses, the identification of viral proteins that bind cis-
acting elements has not been fully explored.  However, the identification of RNA-protein 
interactions with cellular proteins has been better documented.  Cellular proteins have been 
found to bind both the 5’ and 3’ UTRs.  Two identified cellular proteins have been found to bind 
to the 5’ UTR of MHV, hnRNP I or polypyrimidine tract-binding protein (PTB) and hnRNP Q3 
(33, 96).  In addition to poly(A)binding protein (PABP), mitochondrial aconitase along with three 
associated heat shock proteins, and hnRNP A1  have been shown to bind the viral 3’ UTR (97, 
113, 114, 144). Several unidentified cellular proteins ranging from 30 to 142 kDa have also been 
found and likely include one or more of the identified proteins (173).  Binding of these proteins to 
the UTRs is believed to be important for virus replication.  In support of this, PTB and hnRNP 
Q3 were also found to bind to the complementary strand of the 3’ UTR, thus binding to both 
termini of the genome, and therefore likely participants in RNA synthesis (33, 96).  hnRNPA1 
has also been found to bind both the leader sequence and anti-leader sequence 
(complementary leader sequence), and therefore also binds both ends of the genomic RNA 
(70).    
 These and other hnRNP family members have been found to be involved in both RNA 
synthesis and translation of RNA virus genomes such as those for poliovirus and hepatitis C 
virus (1, 22, 62, 79).  For coronaviruses, there is evidence to suggest the identified hnRNP 
proteins are involved in RNA synthesis.  In MHV, PTB-hnRNPA1 binding interactions have been 
proposed to circularize the genome and provide a circular closed loop for replication (70).  
Overexpression or depletion of these proteins resulted in altered MHV growth kinetics (32, 33, 
138).  Alternatively, these proteins do not appear to be involved in translation as the depletion or 
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downregulation of PTB or hnRNP Q3 has been shown to be inconsequential in cap-dependent 
translation of an MHV reporter construct (32, 33).   
 Several of the unidentified cellular proteins have also been found to bind to the UTRs of 
both BCoV and MHV.  No less than eleven cellular proteins have been found to bind to the 3’ 
UTR ranging from 30kDa to 142kDa, some of which may include the already identified proteins 
(143, 173).  In the 5’ UTR, six cellular proteins have been found to bind to cis-acting SL III and 
nine cellular proteins have been found to bind cis-acting SL IV (128, 130).  These fifteen 
unidentified proteins range from approximately 33kDa to 61kDa and could also include one or 
all of the currently identified proteins.  How these proteins may function in virus replication is 
unknown. 
Nonstructural Protein 1/p28  
 The first nonstructural protein (nsp 1) encoded by ORF1a is called p28 due to its 
approximate size of 28kDa.  p28 is cleaved from the ORF 1a polyprotein cotranslationally by the 
viral protease nsp 3 soon after its translation (38, 44, 45, 72, 73).  In MHV, mutation of the nsp 
1-nsp 2 cleavage site results in reduced replication indicating p28 is important for replication 
and cleavage from the polyprotein is important for its function (39).  In BCoV DI RNA replication, 
it has been shown that deletion of the partial nsp 1 coding region results in a loss of  DI RNA 
replication (20).  In studies with an MHV infectious clone, deletion of this region in the viral 
genome was also detrimental to virus replication (18).  Two stem-loops have been predicted to 
exist within the 5’ proximal coding region of nsp 1 and confirmed to exist by RNase structure 
probing.  One of these, SLVI has been shown to be a cis-acting element in DI RNA replication 
(20).  Interestingly, this N-terminal portion of p28 is found in all characterized DI RNAs (14, 15).  
In addition to the requirement for the RNA secondary structure, the translation product of this 
coding region is also required for replication.  In MHV, deletion of p28 using a full length 
infectious clone resulted in deficient or no virus replication (18).  Alternatively, C-terminal 
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truncations did not affect replication (18, 177).  Also, replication of BCoV DI RNA was inhibited 
when the start codon was mutated to a stop codon or frameshift mutations were introduced to 
change the sequence of the partial p28 coding region (20).  Thus there exists a separate 
requirement for both the RNA secondary structure and the protein product of the N-terminal 
region of p28.    
 It is postulated that p28 is part of the viral replication complex, and it was found to 
associate with viral RNA and viral proteins such as the helicase, RdRp, N, and matrix protein. 
p28 has furthermore been shown to directly bind two viral nonstructural proteins, nsp 7 and nsp 
10 (19).  The function of p28 in virus replication remains unknown; however effects on cellular 
processes have been reported.  Cell cycle arrest has been reported to occur when MHV p28 is 
overexpressed in the absence of other viral proteins and this has more recently been observed 
with the SARS-CoV homolog (30, 164).  Other cellular effects reported for both the MHV and 
SARS-CoV nsp 1 protein when expressed in cells, include cellular mRNA degradation and 
translation shutoff (78, 115, 164, 177).  In addition SARS-CoV nsp 1 has been shown to induce 
cytokine dysregulation (94). 
Observations That Led To Research 
 Previous research has focused on cis-acting replication elements that exist within a 5’ 
proximal 421 nucleotide region of the BCoV DI RNA.  This region was initially defined as the 
difference between the replicating DI RNA and the nonreplicating sgmRNA 7.  The 421 
nucleotide region includes nucleotides 74 through 210 of the 5’ UTR and nucleotides 211 
through 495 of the nsp 1 coding region (15).  Thus, it was hypothesized that this region 
contained elements required for replication and therefore sgmRNAs that code for the viral 
structural genes do not replicate. 
 Experiments using the BCoV DI RNA have found that there is a separate requirement for 
both the RNA secondary structure and translation of the partial nsp 1 coding region in the DI 
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RNA.  Translationally silent mutations of a stem-loop structure (SL VI) mapped by RNase 
enzyme probing resulted in a loss of DI RNA replication.  Compensatory mutations that restored 
the stem structure but altered the primary nucleotide sequence restored replication to wildtype 
levels (20).  This implicated that a higher order stem-loop structure within the coding region of 
the first nonstructural protein was an important feature in replication of the DI RNA.  In addition, 
experiments in which the translation product of the partial nsp 1 (p28) coding region was altered 
by a frameshift mutation resulted in a loss of DI RNA replication (20).  From these results it was 
proposed that either the translation product or the act of translation was a replication 
requirement (20, 25). 
 In the research described in Chapter II, a second stem-loop structure (SL V) which was 
mapped immediately upstream of the cis-acting stem-loop VI is shown to be a cis-acting higher 
order structure.  Also, the separate requirements for RNA secondary structure and translation 
led us to hypothesize that the translation product (p28) may be autoregulatory.  Chapter II 
furthermore shows that although p28 does not appear to bind to the cis-acting structures within 
its own coding region, it does interact with other cis-acting elements within the 5’ and 3’ UTRs.  
Experimental data presented in Chapter II and elsewhere (described in the Introduction) has 
demonstrated that p28 binds viral RNA and proteins and appears to have an effect on cellular 
and viral mRNAs.   Using this experimental data in combination with a bioinformatic analysis of 
BCoV p28, putative RNA and protein binding motifs are presented in Chapter IV. 
 To extend our hypothesis that a viral protein may be regulatory, we focused on 
translation regulation and the involvement of the untranslated regions.  The only well 
characterized translation regulatory mechanism for coronaviruses is the -1 frameshifting 
pseudoknot at the ORF 1a/1b junction.  In coronaviruses there is the potential for translation 
regulation to occur in at least three other stages: translation of the viral polyprotein, subgenomic 
mRNAs, and the translation to replication switch.  Currently the only viral protein shown to have 
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an effect on translation is the N protein although a mechanism has not been elucidated (149).  
Furthermore, the leader sequence of the MHV 5’ UTR has also been shown to influence the 
efficiency of translation of a reporter construct in virus infected cells (148).  However, overall 
there has been little investigation into the factors (cellular or viral) that regulate the translation of 
viral proteins and how translation is inhibited and RNA synthesis begins.   
   Thus, we hypothesize that viral proteins are necessary for efficient translation, 
regulation, and may modulate the switch from translation to RNA synthesis.  The first step in 
investigating this is to determine how or if the UTRs affect canonical translation.  Here, an initial 
look at the roles of the untranslated regions in translation in the absence of viral proteins is 
investigated using an in vitro system and renilla luciferase reporter constructs.  Interestingly, a 
BCoV specific 5’-3’ UTR mediated repression of cap-dependent translation was observed.  
Characterization of this phenomenon is described in Chapter III. 
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  Chapter II.  Bovine Coronavirus p28 (nsp1) is an RNA Binding Protein that Binds 
Terminal Genomic Cis-Replication Elements But Not Cis-Acting Stem-Loops V and VI 
within the p28 Cistron 
 
This chapter has been submitted for publication in the Journal of Virology.  Kortney M. Gustin,1 
Bo-Jhih Guan,1 Agnieszka Dziduszko,2 and David A. Brian1,2,*, Departments of Microbiology1 
and Pathobiology2 , University of Tennessee College of Veterinary Medicine, Knoxville, 
Tennessee 37996-0845.  *Corresponding Author.  Work performed by coauthor Bo-Jhih Guan 
includes all experiments concerning SLIII and p28.  Gel-shift experiments with the 3’ UTR and 
p28 were performed by coauthor Agnieszka Dziduszko.  The coauthor’s contributions are noted 
in figure legends. 
 
Introduction 
Coronaviruses (142) cause primarily respiratory and gastroenteric diseases in birds and 
mammals (89, 165).  In humans, they most commonly cause mild upper respiratory disease but 
the recently-discovered human coronaviruses (HCoVs) HCoV-NL63 (157), HCoV-HKU1 (167), 
and SARS-CoV (105) cause serious diseases in the upper and lower respiratory tract.  The 
SARS-CoV causes pneumonia with an accompanying high (~10%) mortality rate (162).  The 
~30 kilobase positive-strand coronavirus genome, the largest known among RNA viruses, is 5’-
capped, 3’-polyadenylated, and replicates in the cytoplasm (106).  As with other characterized 
cytoplasmically-replicating positive-strand RNA viruses (6), translation of the coronavirus 
genome is an early step in replication, and terminally-located cis-acting RNA signals regulate 
translation and direct genome replication (106).  How these happen mechanistically in 
coronaviruses is only beginning to be understood.   
In the highly-studied group 2 mouse hepatitis coronavirus model (MHV-A59 strain) and 
its close relative the bovine coronavirus (BCoV-Mebus strain), five higher-order cis-replication 
signals have been identified in the 5’ and 3’ untranslated regions.  These include two in the 5’ 
UTR required for BCoV DI RNA replication (Fig. 1A) described as stem-loop (SL) III (129) and 
SLIV (130).  Recently, the SLI region in BCoV (26) has been re-analyzed along with the 
homologous region in MHV and is now described as comprising SL1 and SL2 (Fig. 1A), of 
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which SL2 has been shown to be a cis-replication structure in the context of the MHV genome 
(102).  In the 3’ UTR, two higher-order cis-replication structures have been identified that 
function in both DI RNA and MHV genome.  These are a 5’-proximal bulged stem-loop and 
adjacent pseudoknot that potentially act together as a unit (55, 67, 68, 166) and a 3’-proximal 
octamer-associated bulged stem-loop (103, 172) (Fig. 1A).  In addition, the 5’-terminal 65-nt 
leader and the 3’-terminal poly(A) tail have been shown to be cis-replication signals for BCoV DI 
RNA (26, 143).   
In coronaviruses, the 5’-proximal open reading frame of ~20 kilobases (called ORF 1) 
comprising the 5’ two-thirds of the genome is translated to overlapping polyproteins of ~500 and 
~700 kDa, respectively named pp1a and pp1ab (106).   pp1ab is formed by a -1 ribosomal 
frameshift event at the ORF1a-ORF1b junction during translation (106).  pp1a and pp1ab are 
proteolytically processed into potentially 16 nonstructural protein (nsp) end products or partial 
end products that are proposed to function together as the replicase (56).   ORF 1a encodes 
nonstructural proteins 1-11 which include papain-like proteases (nsp 3), a 3C-like main protease 
(nsp5), membrane anchoring proteins (nsps 4 and 6), a potential primase (nsp8), and RNA-
binding proteins (nsp 7/8 complex, nsps 9 and 10) of imprecisely understood function (41, 42, 
56, 58, 74, 108, 125, 175).  ORF 1b encodes nonstructural proteins 12-16 which function as an 
RNA-dependent RNA polymerase, a helicase, an exonuclease, an endonuclease, and a 2’-O-
methyltransferase, respectively (12, 36, 56, 111).   3’ proximal genomic ORFs encoding 
structural and accessory proteins are translated from a 3’-nested set of subgenomic mRNAs 
(106).   
The N-terminal ORF 1a protein, nsp1, in the case of BCoV and MHV is named p28 to 
identify the cleaved 28 kilodalton product (37).  The precise role of nsp1 in virus replication has 
not been determined, but it is known that a sequence encoding an N-proximal p28 region in 
MHV (nt 255-369 in the 738-nt coding sequence) cannot be deleted from the genome without 
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loss of productive infection (18).  Nsp1 also directly binds nsp 7 and 10 (19), and by confocal 
microscopy is found associated with the membranous replication complex (18, 158) and virus 
assembly sites (19).  The amino acid sequence of nsp1 is poorly conserved among 
coronaviruses indicating it may be a protein that interacts with cellular components (2, 141).  In 
the absence of other viral proteins, MHV p28 induces general host mRNA degradation (177) 
and cell cycle arrest (30).  The SARS-CoV nsp1 homolog, a 20 kDa protein, has been reported 
to cause mRNA degradation (78, 115), inhibition of host protein synthesis (78, 115, 164), 
inhibition of interferon signaling (164, 177), and cytokine dysregulation in lung cells (94).   
In this study, we examine the RNA-binding properties of BCoV p28 with the hypothesis 
that it is a potential regulator of translation or replication.  The rationale for this hypothesis stems 
from five observations:  (i)  In the BCoV DI RNA, the 5’-terminal ~one third of the nsp1 coding 
region and the entire N protein coding region together comprise the single contiguous ORF in 
the DI RNA, and most of both coding regions appear required for DI RNA replication (26).  (ii)  
The partial p28 cistron in the DI RNA must be translated in cis for DI RNA replication in helper 
virus-infected cells (20, 25).  (iii)  A similar part of the nsp1 ORF is found in the genome of all 
characterized naturally-occurring group 1 and 2 coronavirus DI RNAs described to date (14, 15).  
(iv)  A cis-acting stem-loop named SLVI is found within the partial p28 cistron in the BCoV DI 
RNA (20).  (v)  Translation, which involves a 5’→3’ transit of ribosomes, and (-)-strand 
synthesis, which involves a 3’→5’ transit of the RNA-dependent RNA polymerase, cannot 
simultaneously occur on the same molecule with a single ORF (7, 80).  Thus, to enable genome 
replication an inhibition of translation at least early in infection for cytoplasmically-replicating (+)-
strand RNA viruses is required (7, 8, 54, 81).  Mechanisms of translation inhibition have been 
described for Qβ viral genome wherein the viral replicase autoregulates translation by binding 
an internal cis-replication element (81), and for the poliovirus genome wherein genome 
circularization inhibits the early translation step (8, 54).  Therefore, since p28 is synthesized 
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early and also contains a cis-replication element in its coding region, we postulated that it is 
autoregulatory with RNA binding properties. 
Here we (i) demonstrate by mutagenesis analysis that the 72-nt SLV, mapping 
immediately upstream of SLVI and within the partial nsp1 ORF, is also a cis-acting DI RNA 
replication element, (ii) show by gel-shift and UV-crosslinking analyses that there is likely no 
binding of an intracellular viral protein to SLV-VI, but there is binding of unidentified cellular 
proteins of ~60 and 100 kDa molecular weight, and (iii) show by gel-shift analysis that 
recombinant p28 purified from E. coli does not bind SLV-VI, but does bind SLs I-IV in the 5’ UTR 
and also the 3’-terminal bulged stem-loop in the 3’ UTR suggesting a possible regulatory role at 
these sites.  Notably, specific binding with ~2.5 μM affinity of p28 to SLIII and its flanking 
regions in the 5’ UTR was observed.  Additionally, we show that under conditions of p28 
overexpression from a sgmRNA there is greatly reduced DI RNA levels but only mild transiently 
reduced levels of viral RNA species.  These results together indicate p28 is an RNA-binding 
protein that may function as a regulator of viral translation or replication, but not through its 
binding of cis-acting stem-loops V and VI within the p28 cistron. 
Materials and Methods  
Cells and viruses.  A DI RNA-free stock of the Mebus strain of BCoV (GenBank # 
U00735) at 4.5 × 108  PFU/ml (25, 26) was grown on human rectal tumor cell line HRT-18 (153) 
as described (26).  Other genome sequences analyzed were those of MHV-A59 (GenBank # 
NC_001846) and SARS-CoV-Toronto (GenBank # NL_004718). 
RNA structure predictions.  Mfold (http://mfold.bioinfo.rpi.edu/) (107, 176) was used to 
predict RNA secondary structures. 
Plasmid constructs.   To make BCoV DI RNA with mutations in SLV, PCR 
mutagenesis (132) was done using pDrep1 DNA.  pDrep1 is a pGEM3Zf(-) (Promega)-based 
plasmid containing a cDNA clone of a naturally occurring 2.2 kb DI RNA of BCoV modified to 
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carry a 30-nt in-frame reporter (26).  For mutagenesis, overlapping primers bordering SLV and 
containing the desired base changes (Table 2-1) and Hpa I and Xba I sites (occurring in pDrep 
1 at nt 150 and 595, respectively) were used for directional ligation into wt pDrep1.  
To make BCoV DI RNA for expressing wt p28 from subgenomic mRNAs, a modification 
of pDrep12.7 (171), which is itself a modification of pDrep1(171), was used and named pDrep-
ISp28.  For this, a 756-nt fragment containing the upstream 7-nt template-switching core and 
flanking sequences for N mRNA (AATAATCTAAACTTTAAGG, a total of 18 nt called the 
intergenic sequence [IS] (87)) and the nsp1 cistron (BCoV genomic nt 211-948, a total of 738 nt) 
flanked by BamH I and Kpn I restriction enzyme sites was used to replace the 198-nt BamH I (nt 
1667)-Kpn I (nt 1865) fragment in pDrep12.7.  For pDrep-ISp281-95 (abbreviated N-term), 
genomic nt 211-495 (encoding nsp1 aa 1-95) were used in place of the full-length nsp1 cistron 
to make the construct, and for pDrep-ISp2895-246 (abbreviated C-term), genomic nt 493-948 
(encoding nsp1 aa 95-246) were used.  To make pDrep-IS-2’O-MT for expressing the 2’-O-MT 
(nsp 16), BCoV genomic nt 20596-21498 replaced genomic nt 211-948 in pDrep-ISp28 between 
the BamH I and Kpn I sites. 
To make RNA probes for gel-shift analyses, primers bordering the cis-replication 
elements in pDrep 1 were used that had incorporated EcoR I and Hind III sites for directional 
ligation into Eco RI/Hind III-linearized pGEM3Zf(-) (Promega).  
To make p28 in E. coli, the nsp1 coding region from BCoV (nt 211-948) was subcloned 
with BamH I and EcoR I site-containing primers into the BamH I/EcoR I site of pET28a(+) vector 
(Novagen).  This construct yielded p28 with a 33-nt upstream 6His/thrombin site/T7-tag-
containing sequence.   
 RNA synthesis.  For synthesis of uncapped (+)-strand transcripts of SLV DI RNA 
mutants for testing mutational effects on DI RNA replication, 2 µg of Mlu I-linearized plasmid 
DNA were transcribed in a 100 µl reaction mix containing 40 U of T7 RNA polymerase
 19
Table 2-1.  Oligonucleotides Used for SLV-VI Studies. 
Oligonucleotidea Polb Sequence (5’→3’) 
Binding 
Region in 
pDrep1c 
pRight-5’ 306/309 + GGATAACCCTAGcAGcTCAGAGGT 294-317 
pRight-3’ 306/309 - ACCTCTGAgCTgCTAGGGTTATCC 294-317 
pLeft-5’ 240/243 + TCGAgCTgCACTGGGCTCCAGAATTTCC 236-263 
pLeft-3’ 240/243 - GGAAATTCTGGAGCCCAGTGcAGcTCGA 236-263 
pRtLt-5’  + CTCGAgCTgCACTGGGCTCCAGAATTTCCcTGGATG 235-270 
pRtLt-3’  - CATCCAgGGAAATTCTGGAGCCCAGTGcAGcTCGAG 235-270 
pRtLt (-loops)-5’ + AGAATTTCCATGGATGTTTGAGGACGCAGA 255-284 
pRtLt (-loops)-3’ - TCTGCGTCCTCAAACATCCATGGAAATTCT 255-284 
pLoops-5’ + CCAGAATTTCCcTGGATGTTcGAaGACGCA 253-282 
pLoops-3’ - TGCGTCtTCgAACATCCAgGGAAATTCTGG 253-282 
pRtLoops-L-5’  + CACTGGGCTCCAGAATTTCCcTGGATG 244-270 
pRtLoops-L-3’ - CATCCAgGGAAATTCTGGAGCCCAGTG 244-270 
pRtLoops-R-5’ + GTTcGAaGACGCAGAGGAGAAGTTGGATAACCCTAGcAGcTCA 270-312 
pRtLoops-R-3’ - TGAgCTgCTAGGGTTATCCAACTTCTCCTCTGCGTCtTCgAAC 270-312 
150-HpaI-5’ + GTTAACAGCTTTCAGCCAGGGACGTGTTG 150-178 
600-XbaI-3’ - TCTAGATTGGTCGGACTGATCGGCC 576-600 
BCoV leader  + GATTGTGAGCG 1-11 
TGEV8(+) - CATGGCACCATCCTTGGCAACCCAGA 1098-1123 
HSVgD(+) - GAGAGAGGCATCCGCCAAGGCATATTTG 1854–1885  
3’UTR (+) - CAGCAAGACATCCATTCTGATAGAGAGTG 2226-2254 
AThe positive and negative symbols in the oligonucleotide name indicate the polarity of the nucleic acid to which the 
oligonucleotide anneals. 
BPolarity of the oligonucleotide relative to the positive strand DI RNA 
CFor probe binding to the negative-strand sequence the numbers correspond to complementary positive-strand 
sequence. 
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(Promega) following the Promega protocol for synthesis of uncapped nonlabeled RNA.  The     
mix was treated with 3 U of RQ1 RNase-free DNase (Promega) and RNA was purified by silica 
matrix affinity using the RNaid kit (MP Biochemicals) and quantified spectrophotometrically.   
For synthesis of (+)-strand radiolabeled RNA probes, 2 µg of Hind III-linearized plasmid 
DNA were transcribed in a 50 µl reaction mix containing  40 U of T7 RNA polymerase 
(Promega) and 120 µCi α32P-UTP (3000 Ci/mmole) (MP Biochemicals).  The mix was treated 
with 3 U of RQ1 RNase-free DNase (Promega) and probes were purified by electrophoresis on 
a 5 or 9% polyacrylamide/7% urea gel.  RNA visualized by autoradiography was eluted from the 
excised gel band overnight in elution buffer (1mM EDTA, 0.5M ammonium acetate), and ethanol 
precipitated.  Cerenkov counts were determined by scintillation counting in water. 
Northern assay for DI RNA replication.  Northern blot assays for detecting reporter-
containing DI RNAs were performed essentially as described (137, 171).  Briefly, cells (~6 × 
106) at ~80% confluency in a 35-mm dish were infected with BCoV at a multiplicity of 10 PFU 
per cell and transfected 1 h later with 500 ng of RNA using Lipofectin (Invitrogen).  At the 
indicated times postinfection, RNA was extracted with Trizol (Invitrogen) and stored in water at -
200C.  For passage of progeny virus, supernatant fluids were harvested at 48 hpi and 300 µl 
was used to infect freshly confluent cells (~8 × 106) in a 35-mm dish (called virus passage 1, 
VP1) from which supernatant fluids at 48 hpi were used to infect new cells (called VP2).  For 
VP1 and VP2, RNA was extracted at 48 hpi.  For electrophoretic resolution in a formaldehyde-
agarose gel, one quarter of the RNA from each dish was used per lane (where one quarter was 
~14, 30, and 44 μg for 1, 24 and 48 hpi, and ∼100 μg each for VP1 and VP2).  Approximately 1 
ng of RNA transcript, identified as RNA in the Northern blot figures, was used as a marker.  
RNA was transferred to Hybond N+ nylon membrane (Amersham) by vacuum blotting and 
membranes were UV irradiated.  Blots were probed with 20 pmoles of γ-32P-end labeled 
oligonucleotide probe at ∼5×105 cpm/pmol.  Probes used were TGEV8(+) or HSVgD(+) for 
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detecting DI RNA progeny and 3’UTR(+) for detecting DI RNA, viral genome and viral 
sgmRNAs.  Probed blots were exposed to Kodak XAR-5 film for 1 to 7 days at -800C for imaging 
and counts were quantified with a PhosphorImager (Molecular Dynamics).   
Sequence analysis of progeny from mutant DI RNA replicons.  Reverse transcription 
with Superscript II Reverse Transcriptase (Invitrogen) was done on RNA extracted at VP1 and 
VP2, and PCR was done with primers BCoV leader(-) and TGEV(+).  PCR products were 
sequenced directly. 
In vitro translation.  500 ng of wt or mutant DI RNA as transcripts from plasmids were 
translated in a 50 µl reaction mix of rabbit reticulocyte lysate (Promega) containing 20 µCi 35S-
Met.  At 90 min, proteins in a 5 µl sample were resolved by SDS-PAGE in a gel of 12% 
polyacrylamide and radioactivity was quantified on the dried gel by phosphor imaging.  
Cell lysate preparation.  BCoV-infected and mock-infected cell lysates were prepared 
essentially as described by Thomson et al (152).  Briefly, cells from a 75 cm2 flask were 
collected by scraping and pelleted cells were resuspended in 100 μl lysis buffer (10 mM HEPES 
[pH 7.5], 3 mM MgCl2, 14 mM KCl, 5% glycerol, 0.5% NP40, 1 mM DTT, 1×Complete Protease 
Inhibitor [Roche]) and incubated on ice for 20 min.  Lysates were clarified by microfuge 
centrifugation at 3000 rpm for 4 min at 40C and aliquots were stored at -800C.  For infected cell 
lysates, cells were infected with an MOI of 10 viruses per cell and lysates were prepared at 6 
hpi.  Protein concentrations were determined by the Bradford assay.  
Protein expression and purification from E. coli.  BL21 (DE3) E. coli cells 
transformed with p28(+)-nsp1 were grown in LB medium containing 34 μg/ml chloramphenicol 
and 25 μg/ml kanamycin until ∼0.6 OD600.  Protein expression was induced with 1 mM IPTG 
(isopropyl-β-D-thiogalactopyranoside) and cells were grown an additional 15 hrs at 15°C.  Cells 
(~10 g) were pelleted at 5000×G, flash frozen in liquid N2, and resuspended with sonication in 
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30 ml lysis buffer (50 mM Tris [pH 8.0], 0.3 M NaCl, 10 mM imidazole, 5% glycerol, 1 mM βME, 
1 mM PMSF [phenylmethanesulphonylfluoride], 1× EDTA-Free Complete Protease Inhibitor 
[Roche], and 25 U/ml Benzonase endonuclease [Novagen]).  Fusion protein was purified by 
chromatography on Ni-NTA superflow resin (Qiagen) and p28 was released in column by 
thrombin cleavage and concentrated by filtration on YM-10 Centriprep/Centricons cellulose 
membranes (Millipore). 
Gel-shift assays.  The method of Andino et al (5) as modified by Silvera et al (140) and 
as described here was used.  Briefly, ~4×104 cpm of α-32P-labeled RNA probe (1-5 ng) was 
incubated in a 15 μl binding reaction mix containing 5 mM HEPES (pH 7.9), 40 mM KCl, 2 mM 
MgCl2, 4% glycerol, 2 mM DTT, 0.25 μg/μl heparin, 1 U/μl RNasin [Promega], 0.5 μg/μl yeast 
tRNA, 1× EDTA-Free Complete Protease Inhibitor [Roche] and either 20 μg HRT cell lysate 
protein, or purified E.coli-expressed fusion protein to make [5-30 μM] final.  The mix was 
preincubated without probe for 10 min at 300C and then for an additional 10 min after adding 
probe.  2 μl of 50% glycerol was added and reaction products were electrophoretically 
separated on a 5% nondenaturing polyacrylamide gel for approximately 4 hours at 40C.  Gels 
were dried and exposed to Kodak XAR-5 film and results were visualized by autoradiography 
and quantified by phosphor imaging. 
UV cross-linking.  The method essentially as described by Pestova et al (124) was 
used.  Briefly, ~3×105 cpm of α-32P-labeled RNA probe in 15 μl binding reaction mix with cell 
lysate was incubated as described for the gel-shift assay and irradiated on ice at 3 mwatts/cm2 
for 30 min using a UV Stratalinker 1800.  Irradiated reaction mixes were treated with 2.5 U 
RNase A, 100 U RNase T1, and 0.1 U RNase CV1 (all from Ambion) for 30 min at 370C and 
proteins were resolved by SDS-PAGE.  Dried gels were exposed to Kodak XAR-5 film for 
autoradiography. 
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Bioinformatics.  Potential RNA and protein binding domains in BCoV and MHV nsp1 
were predicted with the SMART program (http://smart.embl-heidelberg.de/) (95, 133).  
Sequence alignments were made with Vector NTI Suite 8 (Invitrogen). 
Results 
Stem-loop V mapping within the p28 coding region immediately upstream of SLVI is a required 
cis-acting signal for DI RNA replication.   
A 30-nt stem-loop, SLVI, mapping at nt 101-130 within the 5’-terminal partial p28 (nsp1) 
coding sequence (genomic nt 311-340) (Figs. 2-1A and 2A) was recently identified as a cis-
acting replication element for BCoV DI RNA (20).  Although its cis-replication feature remains to 
be tested in the context of the full-length viral genome, this stem-loop along with the frame-
shifting pseudoknot at the ORF 1a/1ab junction (16) are to our knowledge the only higher-order 
cis-replication elements known within coronavirus ORF 1 (20).  Just upstream of SLVI is a 
structure-mapped 72-nt stem-loop, SLV at nt 29-100 within ORF 1a (genomic nt 239-310) (Fig. 
2- 2A) (20), whose function as a cis-acting higher-order structure has not yet been tested.  To 
examine its potential cis-acting role in BCoV DI RNA replication, synonymous base substitutions 
designed to disrupt base-pairings in a helical region and compensatory mutations designed to 
restore base-pairings were tested.  Silent helix-disrupting substitutions were feasible only in the 
downstream side of the bottom-most stem for which changes U306C and U309C were made to 
form mutant pRt and transcripts were tested for DI RNA replication.  Following transfection into 
BCoV-infected cells, pRt DI RNA accumulation as determined by a visible band in Northern 
analysis was undetectable at 48 hpi and was present only at low levels in virus passages (VP) 1 
and VP2 when compared to wt DI RNA levels (Fig. 2-2B).  Sequence analysis of progeny RNA 
showed only wt revertants in VP2 indicating that the mutant had replicated poorly, if at all, and 
revertants with wt sequence, likely arising through recombination with the 5’ end of the helper 
virus genome, were selected (data not shown).  However, when base pairings were restored by
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Figure 2-1.  RNA Structures in the BCoV Genome Tested for p28 Binding.   A.  BCoV 5’-terminal and 3’-terminal cis-acting 
RNA stem-loop structures and flanking sequences identified for BCoV DI RNA replication.  Regions of the genome are identified 
and stem-loop cis-replication elements are identified schematically.  Open boxes at nt 100 and 211 identify AUG start codons for 
the short upstream ORF and ORF 1, respectively.  A closed box at nt 124 identifies the UAG stop codon for the short upstream 
ORF.  Shown below the stem-loop structures are the RNA segments used as [32P]-labeled probes in the gel-shift assays.  B.  
Gel-shift assays for probes when used with purified p28.  Protein-RNA complexes (C) identifying a shifted probe are labeled 
(coauthor contributions: SLIII by B.Guan, BSL-pk and 8mer-BSL by A.Dziduszko). 
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Figure 2-2. Mutations in Stem-Loop V that Affect Replication of wt BCoV DI RNA.  A.  
Mapped structures of SLIV-VI and predicted structure of SLVII in wt BCoV DI RNA (as produced 
from pDrep1).  Note that in mutant pΔ397-498 (Brown et al, 2007), nt 397-498 are deleted which 
resulted in no loss of replicating ability.  In mutant pΔ397-498 DI RNA, the N ORF begins at nt 
397.  The mutations in SLV are as follows:  Left, A240G, A243G; Right, U306C, U309C; Loops, 
A264C, U273C, G276A; Rt/Loops, U306C, U309C, A264C, U273C, G276A.  B.  Northern 
analysis of wt and SLV mutant DI RNAs.  The calculated free energies (ΔG) of wt and mutated 
SLV’s are shown.  The Northern analyses used a [32P]-radiolabeled probe specific for the 
reporter sequence (30-nt TGEV reporter) on extracted RNA at the indicated times post-infection.  
VP1, virus passage 1; VP2, virus passage 2.  Replication is based on the presence of DI RNA 
by Northern analysis in VP2, and reversion is judged from the sequence of the RT-PCR product 
in VP2 RNA. If only wt (i.e., reverted sequence) is found in VP2, the mutant is considered dead.  
C.  In vitro translation of wt and mutant DI RNA transcripts.  Upper panel:  [35S]-radiolabeled 
translation product.  Lower panel:  EtBr-stained RNA transcript used for in vitro translation. 
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compensatory mutations A240G and A243G in mutant pLtRt, replication as evidenced by 
accumulation of pLtRt DI RNA in Northern blots was restored to near wt levels in VP1 and VP2 
(Fig. 2-2B) and mutations on both sides of the stem were retained in VP2 as revealed by 
sequence analysis (data not shown).  A240G and A243G alone in mutant pLt were not predicted 
to disrupt basepairing in the stem and, consistent with this structure, their presence alone did 
not block DI RNA replication as evidenced by DI RNA accumulation in Northern blots (Fig. 2-2B) 
and sequence analysis.  These results together indicate that optimal replication of DI RNA 
requires base pairing in the lowest helical region of SLV.  Furthermore, when three silent point 
mutations were made in the upper loops of SLV, namely A264C, U273C and G276A (Fig. 2-2A), 
to form the mutant named pLoops, the overall mfold-predicted structure of SLV was only slightly 
changed (data not shown) and progeny DI RNA from pLoops, although slow in accumulating, 
retained the parent mutations in VP2.  However, when the mutations in pLoops were combined 
with those in pRt to form pRt/Loops, there was additional structure disruption as predicted by 
mfold and accumulation was further impaired over pRt (Fig. 2-2B).  That is, accumulation of 
pRt/Loops was not visible by Northern analysis at 48 hpi or in VP1 or VP2 (Fig. 2-2B) even 
though small amounts of wt progeny and progeny with reversions only at 306 and 309 were 
found by sequencing RT-PCR products (data not shown).  These results indicate that the overall 
higher-order structure of SLV, in addition to integrity in the lower stem, contributes to optimal 
BCoV DI RNA replication.   
Translation of the partial 1a ORF has been shown to be a cis-requirement for DI RNA 
replication (20, 25).  To rule out that the observed loss of replication for SLV mutants was a 
result of unforeseen blocked translation arising from altered secondary structure (85), capped 
transcripts of wt and two selected mutants that did not replicate were translated in vitro in rabbit 
reticulocyte lysate and the products compared.  Proteins translated in the presence of 35S-
methionine from equal amounts of RNA (Fig. 2-2C) were evaluated by SDS-PAGE and the 
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results showed that wt, pRt, and pRt/Loops translated at comparable levels (Fig. 2-2C).  Thus, 
the observed decreases in RNA accumulation can be attributed to defects in RNA synthesis and 
not defects in translation. 
p28 binds cis-replication structures in the 5’ and 3’ untranslated regions, but not cis-acting stem-
loops V and VI in the 5’ partial p28 coding region.   
 To test our hypothesis that p28 binds the 5’-proximal cis-replication elements SLV and 
SLVI within its ORF, two approaches were taken.  In the first, evidence of viral protein binding to 
the SLV-VI probe was sought by gel-shift experiments with lysates of infected cells.  In this 
case, when 32P-labeled SLV-VI probe was tested three retarded protein complexes were found 
that were also present with lysates from uninfected cells (Fig. 2-3A).  Thus, no complexes were 
found that were unique to BCoV-infected cells suggesting that SLV and VI are bound by cellular 
but not viral proteins (described further below).   
In the second approach, binding was sought with recombinant p28 purified from E. coli.  
When purified p28 was incubated with 32P-labeled SLV-VI, SLV, SLVI, or (putative) SLVII 
probes, no gel shifting was observed, although shifting was found with other terminal cis-acting 
structures noted below indicating by this second method that p28 is probably not binding cis-
acting SLV and VI (Fig. 2-1B).   
 Inasmuch as coronaviral proteins other than p28 have been shown to bind cis-replication 
structures, namely, nucleocapsid protein (N) binds the 5’-proximal SLII region (116, 147, 148), 
2’-O-methyltransferase (nsp 16) binds the 3’-terminal octamer-associated bulged stem-loop 
(Dziduszko, et al, unpublished), and an unknown viral protein(s) from infected cell lysates binds 
SLIII (Raman and Brian, unpublished), we systematically sought the binding of p28 to the three 
5’ UTR-located cis-replication elements SLI-II, SLIII and SLIV, and two 3’-UTR-located cis-
replication elements, the bulged stem-loop-pseudoknot and the octamer-associated bulged 
stem-loop.  Binding of p28 to these would suggest other possible sites for p28 regulation of
 29
 
 
 
A.      B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    C. 
 
 
 
 
 
 
 
 
Figure 2-3. Cellular Proteins but Apparently No Viral Proteins From Cell Lysates Bind the 
SLV-VI Probe.  A.  Three gel-shift complexes are formed with lysates of uninfected and infected 
cells with SLV-VI probe.  B.  Protein-RNA complexes with SLV-VI probe are destroyed by 
proteinase K treatment.  C. Proteins of 100 and 60 kDa from uninfected cell lysate UV cross-link 
to the SLV-VI probe. 
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 translation or RNA synthesis.  In gel-shift experiments, p28 was not found to bind the 3’-
proximal bulged stem-loop-pseudoknot, but was found to weakly bind 5’-proximal SLI-II and 
SLIV, to moderately bind the 3’-terminal octamer-associated bulged stem-loop, and to 
quantitatively shift the probe representing 5’ SLIII with its extended flanking sequences (SLIII-
Long) (Fig. 2-1B).  Additionally, it was not found to bind the 5’-proximal uncharacterized putative 
SLVII in the partial p28 coding region (Fig. 2-1B).  These results indicate p28 is an RNA-binding 
protein that may function to regulate RNA translation or replication through its interaction with 5’ 
or 3’ cis-replication elements, but not through binding to SLV-VI.    
p28 binds SLIII and its flanking sequences with specificity and micromolar affinity.   
 Since p28 caused a quantitative shift in the SLIII-Long probe, we sought to establish 
both its specificity and affinity of binding to SLIII-Long (SLIII with 28-nt upstream and 67-nt 
downstream flanking sequences), as described in Figure 2-1, and SLIII-short (SLIII with only 10-
nt upstream and 10-nt downstream flanking sequences) which nearly represents SLIII proper.  
Figure 2-4A, lane 1, shows that the SLIII-Long probe migrates as upper and lower bands, 
probably representing two folded forms of the probe.  Lane 2 shows approximately 50% of the 
lower form and all of the upper form of the probe fully shifting positions with 2.5 μM p28 
indicating a Kd of ~2.5 μM for p28 binding to SLIII-Long.  Fig. 2-4A, lanes 5-7, show a complete 
inhibition of SLIII-Long shifting with 5, 10 and 15 μg of unlabeled probe, representing 2,500, 
5,000, and 7,500 molar excess over labeled probe, respectively, whereas no inhibition was seen 
with 5, 10 and 15 μg of tRNA.  These results together show specific binding of p28 to SLIII-
Long.   Fig. 2-4B, lane 1, shows the SLIII-Short probe migrating as a single band.  Lanes 2-4 
show far less than quantitative shifting of the probe to an upper band and thus a binding affinity 
was not determined by these experiments.  Lanes 5-7, however, show that a band shifting with 
2.5 μM protein was completely inhibited by the addition of 4, 8 and 12 μg unlabeled SLIII-Short
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Figure 2-4.  Gel-Shift Analysis of Purified BCoV p28 Binding to SLIII.  A. SLIII-Long.  Lane 
1, probe alone showing upper and lower forms.  Lanes 2-4, shifted bands into lower (C1) and 
upper (C2) complexes that form with the indicated amounts of protein.  Lanes 5-7, competition 
of protein binding with 5, 10, and 15 μg of unlabeled SLIII-Long RNA.  Lanes, 8-10, competition 
of protein binding with 5, 10, and 15 μg of tRNA over and above the tRNA in the binding buffer 
present in all lanes.  B.  SLIII-Short.  Lane 2, probe alone.  Lanes 2-4, shifted band with the 
indicated amounts of protein.  Lanes 5-7, competition of protein binding with 4, 8, and 12 μg of 
unlabeled SLIII-Short RNA.  Lanes 8-10, competition of protein binding with 4, 8, and 12 μg 
tRNA over and above the tRNA in the binding buffer present in all lanes (All work presented in 
this figure was performed by coauthor B.Guan).  
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probe, respectively, whereas lanes 8-10 show no inhibition of binding with 4, 8, and 12 μg of 
tRNA, respectively.  These results show weaker but still specific binding of p28 to SLIII-Short.  
Together, the results show that whereas SLIII per se is probably a specific target for p28, the 
affinity of binding is greatly increased with the presence of its extended flanking sequences. 
Unidentified cellular proteins of ∼60 and 100 kDa molecular weight bind cis-acting stem-loops V 
and VI.    
 With the use of 32P-labeled SLV-VI probe, three retarded protein-RNA complexes were 
found by gel-shift experiments that appeared the same in both infected and uninfected cells 
(Fig. 2-3A).  In each case, complex formation was protein-dependent since all were destroyed 
by protease treatment (Fig. 2-3B).  To determine the number and molecular weights of bound 
cellular proteins, UV-crosslinking followed by RNase digestion and SDS-PAGE was done (Fig. 
2-3C).  Proteins UV-crosslinked to the 32P-labeled RNA would be labeled by virtue of covalently 
bound short 32P-labeled RNA tags.  Proteins of ~60 kDa and ~100 kDa molecular weight were 
found to cross-link (Fig. 2-3C).  The identity of these proteins and the significance of their 
interactions with SLV and VI remain to be determined.   
The p28 ORF positioned for sgmRNA overexpression from DI RNA leads to long-term inhibition 
of DI RNA accumulation but to only transient inhibition of viral RNA.   
 To determine whether higher than normal levels of p28 expression have an effect on 
BCoV replication as might be expected of a regulatory protein, BCoV nsp1 cistron was cloned 
into a characterized BCoV DI RNA vector at a site known to express subgenomic RNA in 3-fold 
molar excess over viral genome (Fig. 2-5A) (171).  This method of expression does not involve 
a non-coronaviral expression system and the expressed protein would presumably be available 
to the viral replication machinery (136).  When BCoV-infected cells were transfected with 
transcripts of DI RNA pDrep12.7 (wt) (171), pDrep-ΔISp28 (which is a p28 cistron-containing DI 
RNA construct missing the 18-nt IS transcription start signal), or with transcripts of pDrep-IS-2’-
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Figure 2-5.  Detrimental Effects of p28 Expression From Subgenomic mRNA in DI RNA.  
A.  Map of DI RNA constructs for expressing the full-length p28, the N-terminal 95 aa, and the 
C-terminal 152 aa of p28.  The intergenic sequence (IS) used to induce sgmRNA transcripts for 
p28 expression is the 18-nt sequence upstream of the BCoV N mRNA (sgmRNA 7) (see text).  
B.  Northern analysis of in vivo-generated transcripts of wt and truncated p28 constructs shown 
in panel A as identified by a probe specific for DI RNA (HSVgD reporter).  Results from control 
constructs are also shown.  ΔISp28 represents a construct identical to pDrep-ISp28 except that 
the 18-nt IS is deleted.  2’O-MT represents a construct identical to pDrep-ISp28 except that the 
nsp 16 ORF replaces the nsp1 ORF.  C.  Quantitative summary of PhosphorImager data 
collected from data in panel B.  D.  Northern analysis of viral RNA probed with a 3’end-specific 
probe (3’UTR(+)).  Subgenomic mRNAs 6 and 7 are identified.  E. and F.  Quantitative summary 
of phosphor imaging data shown in panel D for sgmRNA 6 and sgmRNA 7, respectively.  
Asterisks identify the relative quantities of sgmRNA 6 and sgmRNA 7 for the p28 and wt 
constructs. 
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O-MT (designed to express nsp 16 from an identical IS signal) and evaluated by Northern 
analysis, abundant levels of DI RNA for each was observed with a probe that detects the 
downstream reporter sequence (HSVgD) (Fig. 2-5B).  However, with RNA from infected cells 
transfected with DI RNA designed to express the full-length p28 cistron from a sgmRNA (i.e., 
pDrep-ISp28), no DI RNA progeny were detected at any timepoint (Fig. 2-5B and C).  This result 
was not an effect of the p28-coding RNA in the DI RNA since progeny were made from pDrep-
ΔISp28 which contains the same p28 coding sequence.  Interestingly, reduction in viral genome 
and sgmRNA levels with p28-expressing DI RNA was small and short-lived when compared to 
expression levels in pDrep12.7-transfected cells (Fig. 2-5D and E).  That is, a 2-fold reduction in 
viral sgmRNAs 6 and 7 was observed at 24 h post-transfection (note asterisks in Fig. 2-5E) but 
after this time wt levels were reached.  We interpret these results to mean that p28 was 
expressed from sgmRNA and that translation or replication of the DI RNA was more sensitive to 
the effects of p28 than that of viral genome or sgmRNAs.  Interestingly, inhibition of DI RNA 
accumulation was observed not only with expression of full-length p28 from a sgmRNA, but also 
with expression of the C-terminal region of p28 (genomic nt 493-948, aa 95-246) representing a 
part of the genome that can be deleted without loss of viral viability (Fig. 2-5B and C) (18).  Less 
but still significant inhibition was seen with the N-terminal region of p28 (genomic nt 211-495, aa 
1-95) at 24 h postinfection, which contains a 30-nt part of the MHV nsp1 coding region (nt 255-
369) required for MHV genome replication (18, 47).  These results together suggest that the 
RNA encoding p28, or components of p28, or both, have a detrimental effect in trans on DI RNA 
translation or DI RNA synthesis when over-expressed.    
Discussion  
 Here, we test the hypothesis that p28 (nsp1) of BCoV, the first replicase protein to be 
synthesized and proteolytically released, is an RNA-binding protein that binds the cis-acting 
SLVI replication element mapping within its coding sequence.  Binding of p28 to this structure 
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would identify a potential means for autoregulation of gene expression.  The rationale for this 
hypothesis is stated in the Introduction.  Although in this study we found no evidence of p28 
binding to the intra-cistron SLVI (20), or to a newly-identified SLV cis-acting replication signal 
mapping immediately upstream of SLVI within the p28 cistron (this study), binding was found at 
other sites within the 5’ and 3’ UTRs that might serve to regulate translation or replication.  
Notably, binding to a long form of cis-acting stem-loop III in the 5’ UTR with ∼2.5 μM affinity was 
found.   
To our knowledge, this is the first report of an RNA-binding property for coronavirus 
nsp1.  While we tested binding here to only specific terminal regions of genomic RNA, the 
presence of multiple binding sites suggests possible broad spectrum binding properties that 
might be important for binding other sites in the viral genome, and might be mechanistically 
relevant to the variety of cellular responses to coronavirus infection noted in the Introduction.  
Binding of nsp1 to cellular RNAs, for example, might induce pathogenic cellular responses.  To 
date, however, only protein-protein interactions have been evaluated in these processes.   
With regard to direct involvement of p28 in virus replication, several possibilities can be 
envisioned that will need testing.  (i)  p28 bound to SLIII (or SLsIII and IV) might repress 
translation of ORF 1.  The moderately high affinity of p28 for the long form of SLIII in the 5’ UTR, 
and perhaps the lesser but still specific affinity to SLIV, is consistent with results of an earlier 
study showing a 12-fold repression of translation in BCoV-infected cells for a reporter mRNA 
carrying the 210-nt genomic 5’ UTR but not one carrying the 77-nt sgmRNA 7 5’ UTR (135).  
That is, SLIII and SLIV are present in the 210-nt genomic 5’ UTR that experienced repression 
but not in the 77-nt sgmRNA 5’ UTR that experienced no repression (135).  The molecules 
tested in these experiments had identical 3’ UTRs (135).  If the observed repression is a 
function of a viral protein as postulated (135) then p28 becomes a candidate for this function.  It 
is intriguing that SLIII contains some portion of a short upstream ORF found in virtually all 
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coronavirus genomes (129).  Although the function of the upstream ORF has yet to be found, 
conceivably it, or its translated product, plays a role in regulating translation or RNA replication, 
and p28 by binding SLIII may influence these processes.  Based on precedents in other well-
studied (+)-strand RNA viruses, an inhibition of translation might facilitate (-)-strand synthesis in 
a couple of ways.  (a)  p28 binding might block ribosomal transit and enable initiation of (-)-
strand synthesis.  (b)  p28 might interact with SLs I-IV and also the 3’-end, or other 3’ end-
binding components, to form a circular molecule that functions to inhibit translation and enable 
initiation of (-)-strand synthesis as has been shown for picornaviruses (8, 54).  (ii)  p28 might 
interact with a membrane anchoring protein to bring the genome into the membrane-protected 
replication compartments where the viral replication complex assembles and presumably 
functions in the (mostly) absence of the cellular translation machinery (136, 159).  This 
mechanism too has precedent in nodaviruses and several plant viruses (160).  (iii)  p28 by 
binding directly to the very 3’ end of the genome might take part in replication complex formation 
and initiation of (-)-strand synthesis.  (iv)  p28 through  its affinity for SLIII in the 5’ UTR may 
play a role in RdRp template switching events that direct leader formation at the 3’ end of 
sgmRNA-length templates for sgmRNA synthesis (170, 171).  (v)  Finally, p28 might function in 
the initiation of nascent (+)-strands from the 3’ end of the (-)-strand antigenome.  For this, a 
systematic study has not been made but we have learned that SLIII does specifically, although 
weakly, bind the (-)-strand counterparts to SLIII-Long and SLIII-Short (data not shown), 
suggesting a possible role for p28 in (+)-strand synthesis. 
 At this time we are unable to explain how an overexpression of p28 affects the 
accumulation of DI RNA more than genome and sgmRNAs, but it is possible that the DI RNA is 
simply more sensitive to p28 function, or that it is in a different membranous compartment than 
the genome and sgmRNAs and therefore experiences a higher concentration of p28.  The fact 
that both the N-terminal and C-terminal regions affect accumulation suggests there are many 
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functional domains on p28 for regulation.  Nevertheless, a nearly complete repression of DI 
RNA accumulation and a 2-fold repression of viral sgmRNA abundance, even if short-lived, is 
evidence that p28 has an effect on viral mRNA expression. 
 Both the identity and function of the ∼60 and 100 kDa cellular proteins that bind SLV-VI 
remain to be determined.  Curiously, six cellular proteins with molecular masses of 25 to 58 kDa 
but no viral proteins were found to bind SLIV in the 5’ UTR (130).  The arrangement of three cis-
acting elements in close proximity suggests they might function together as a larger complex.  
Although a relationship between cellular proteins binding SLV-VI or SLIV-VI and translation may 
exist, it is also possible that the cellular proteins play a role in targeting the viral genome to the 
membranes making up the replication compartment (159).    
 Where is the RNA binding domain in p28?  Bioinformatics analysis of the BCoV p28 
amino acid sequence predicts no obvious RNA binding domain but does reveal a potential Zn 
finger with similarity to RNA binding motifs (21, 60).  This domain (aa 34-75), common to both 
BCoV and MHV, is highlighted in Figure 2-6.  It has also been noted that an 8-amino acid C-
proximal domain of unknown function, also highlighted in Fig. 6, is conserved among all group 2 
coronaviruses including the SARS-CoV and the positively-charged surface this domain could be 
an RNA binding site (2).  The functional RNA binding domain in p28, however, remains to be 
empirically determined.   
We conclude that together the results indicate that p28 is an RNA-binding protein that 
may function as a regulator of viral translation or replication, but not through the binding of 5’-
proximal cis-acting stem-loops V and VI within its coding region.  How and where p28 functions 
as an RNA-binding protein, and how SLV and VI function as cis regulatory structures are 
questions that remain to be answered. 
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Figure 2-6.  Aligned Amino Acid Sequences for nsp 1 in BCoV (p28), MHV (p28), and 
SARS-CoV (p20).  The arrowhead identifies the separation site of BCoV p28 into the N-terminal 
and C-terminal parts studied in Fig. 5.  The potential zinc finger-like RNA-binding domain in 
BCoV and MHV (nt 34-75) is identified by highlighting.  A highly similar 8-aa sequence in nsp1 
of all three viruses identifying a potential positively-charged region of the protein is identified by 
highlighting.  Numbers refer to amino acid positions in the BCoV sequence.  Regions in the 
proteins coinciding with the coding regions harboring SLV and SLVI are indicated. 
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Chapter III.  Cap-Dependent Translation of mRNA with Coronavirus 5’- and 3’- 
Untranslated Regions is Repressed in the Absence of Viral Proteins 
 
Introduction 
 Coronaviruses primarily cause respiratory and gastroenteric diseases in birds and 
mammals and have been the subject of increased research since the appearance of SARS in 
2003  (89, 165).  Since that time new coronaviruses have been isolated from many different 
hosts including bats and humans.  Unlike SARS-coronavirus, which causes severe lower 
respiratory tract disease in humans, most human coronavirus infections cause mild upper 
respiratory disease (77, 162).   
 Bovine coronavirus (BCoV) like all coronaviruses is a positive-sense, single-stranded 
RNA virus with a 5’ cap and 3’ poly(A) tail (106).  Translation of the coronavirus genome is 
thought occur via a closed loop or circular complex through interactions with the 5’ cap binding 
complex eIF4F and 3’ poly(A) tail-poly(A) binding protein (PABP) interaction, the same as many 
cellular mRNAs, in order to produce viral proteins necessary for RNA synthesis and replication 
(15).  With over twenty potential protein products, regulation of translation to produce both 
structural and nonstructural proteins is likely an important process in the replication cycle.  
Regulation of protein synthesis, or translational control, can be expected to occur in at least 
three stages of virus replication: genome translation to produce the replicase polyprotein, 
subgenomic mRNA translation to produce structural and accessory proteins, and a translation to 
replication switch.  A fourth stage of translation regulation during coronavirus replication is 
known to occur during translation of the replicase polyprotein.  A -1 frameshifting pseudoknot 
located at the ORF1a/1b junction results in translation of the ORF 1b replicase proteins (16, 17).   
 In coronaviruses, cis-acting replication elements have been found within the 
untranslated regions (UTR) and may function in translation.  To date six cis-acting elements in 
the 5’ and 3’ UTRs have been identified and shown to be important for genome or DI RNA 
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replication (15).  There are three elements in the 5’ UTR including the leader region containing 
SLI and II, SLIII, and SLIV (27, 129, 130).  In the 3’ UTR a bulged stem-loop and adjacent 
pseudoknot, a terminal stem-loop with a conserved octamer sequence, and a poly(A) tail have 
been shown to be cis-acting (68, 103, 143, 144, 166).   
 Currently, only the 5’ UTR leader sequence has been shown to be important for 
translation in MHV infected cells.  The entire 5’ leader sequence has been shown to enhance 
translation of a reporter construct in virus infected cells and a higher order structure, SLII, within 
the leader sequence has been shown to be necessary for efficient translation of a reporter 
construct (102, 148).  Because the leader sequence is present on the genomic RNA and all 
subgenomic mRNAs (sgmRNAs), it appears to be one element important for translation of all 
viral RNAs.  (148).  The viral nucleocapsid protein (N) is currently the only viral protein shown to 
enhance translation in infected cells (149).  This protein has also been shown to bind the leader 
sequence, potentially exerting its effect on translation directly through RNA-protein interactions, 
although this has not been confirmed experimentally  (117, 147). 
 As the first step in a systemic study of translational control of coronaviruses and to 
understand the effects of the viral UTR sequences on translation of genomic and subgenomic 
mRNAs, luciferase reporter constructs with the BCoV 5’ and 3’ UTRs were translated in vitro 
and in the absence of all viral proteins.  In this system, both the 5’ and 3’ UTRs were found to 
independently enhance translation.  Unexpectedly, however, the translational advantage 
conferred by cap-dependent translation initiation was repressed when both UTRs were used, 
suggesting an inhibitory 5’-3’ mechanism.   Further analysis demonstrated the repressive effects 
to be localized within the viral leader sequence and a higher-order structure in the 3’ UTR.  
These results show a repression of translation that is (i) independent of viral proteins, (ii) 
implicates a 5’-3’-end interaction that is likely mediated by cellular proteins, and (iii) suggests 
cap-dependent translation may require the assistance of viral protein(s). 
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Materials and Methods 
 Viral Sequence.  Viral sequences used were from bovine coronavirus Mebus strain (66, 
92), Genbank # U00735. 
 Constructs. Renilla luciferase (RLuc) reporter sequence was obtained using AmpR 
[696] pBS-35S:hRLUC (Packard version) (a gift from A.von Arnim Lab).  RLuc constructs were 
cloned into plasmid pGEM3zf- (Promega) using NgoM IV and Hind III restriction sites (Fig. 3-
1A).  The parent construct, containing the complete viral 5’ and 3’ UTRs was generated using 
overlap PCR in which the BCoV DI RNA was used as the template DNA.  This construct, 
UTR210-288, contains the entire 210nt 5’ UTR, 288nt 3’ UTR, and a poly(A) tail (~65As) (Fig. 3-
1B).  The T7 promoter sequence was placed downstream of the NgoM IV restriction site using 
the PCR primer to ensure the first nucleotide transcribed was the authentic viral 5’ base.  The 
coding region start codon was placed immediately upstream of a BamH I restriction site in order 
to maintain the exact viral 5’ UTR.  Designing the constructs in this manner resulted in every 
construct having the same base, G at the +4 position, altering the BCoV native Kozak context (T 
at +4, nt214).  Similarly, the stop codon at the end of the coding region was placed downstream 
of a Hind III restriction site.  5’ and 3’ UTR modifications were made by replacing the viral 
wildtype sequence with PCR generated fragments using Ngom IV and BamH I (5’ UTR) or 
double Hind III restriction sites (3’ UTR) (Fig. 3-1A).  Polyadenylated 3’ UTRs were made by 
using 2 rounds of overlap PCR, one to generate the 3’ UTR sequence with a poly(A) tail and 
another to fuse the UTR with the rest of the construct.  All viral sequences were cloned using 
BCoV pDrep 1 as the template DNA (26).  The sequence for 5’OPT.UTR was designed based 
on the optimal sequence context from Kozak (82).  5’-GAATACTCCCCGCCGCCACC-3’. The 
sequence for the 40nt 3’ UTR is vector sequence from the pGEM vector cloning site with some 
modifications to eliminate unwanted restriction sites or start codons, 5’-
GAATACTCAGCTTGCCCGCTGCAGGTCGACTCTAGAGTGC-3’.  Construct names are given 
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Figure 3-1.  Renilla Luciferase Constructs. A.  Renilla Luciferase Construct Design. BCoV 5’ 
and 3’ UTRs were exchanged using Ngom IV-BamH I or Hind III-Hind III restriction sites.  
Constructs were linearized with Mlu I and RNA transcribed from a T7 promoter.  B.  Renilla 
Luciferase Construct Diagrams.  Construct names are given as:  5’ UTR sequence – 3’ UTR 
sequence. 
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Figure 3.1, cont.  Part B.
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as 5’ UTR sequence – 3’ UTR  sequence and diagrams are shown in Figure 3-1B and Appendix 
II, Figure A2-5).  Oligonucleotides used for constructs are listed in Table 3-1. 
 RNA synthesis.  2μg of Mlu I linearized DNA was used for RNA transcription.  Capped 
RNAs were synthesized using T7 Message Machine (Ambion) and uncapped RNAs were 
synthesized using T7 RNA polymerase (Promega) following the manufacturer’s protocols. 2 U of 
RNase-free DNase was added to reaction mixtures and RNA was purified using the RNaid RNA 
purification kit (MP Biomedicals).  Cap incorporation (m7G(5')ppp(5')G) under these conditions 
is estimated to be 80% (Ambion).  RNAs were quantitated using a spectrophotometer and 
formaldehyde gel electrophoresis. 
 in vitro translation.  Translations of RLuc RNAs were performed using rabbit 
reticulocyte lysate (Promega).  100ng of RNA was added to each 50μl reaction and translation 
reactions were performed following the manufacturer’s protocol (Promega).  Reactions were 
incubated at 30°C for 90 minutes and 2.5μl aliquots were taken at the indicated times and used 
in the luciferase assay.  Independent translation reactions for each construct were performed a 
minimum of three times.   
 Luciferase assay.  Renilla luciferase assay reagent (Promega) was added to each 2.5μl 
aliquot and luciferase activities determined using a TD20/20 luminometer.  Results are 
presented as the average of three readings per sample and at least three independent 
experiments.  Translation results for each construct are shown in Appendix II, Table A2-1.  p-
values were calculated using the Student’s t-test. 
 Radioactive in vitro translation. Translation reactions using 20μCi 35S-Met and 500ng 
of RNA in a 50μl reaction were performed following the manufacturer’s protocol (Promega) as 
described above.  A 5μl aliquot was taken at 90 minutes and used in SDS-PAGE.  Gels were 
dried and results were visualized and quantitated using a phosphorimager. 
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Table 3-1.  Oligonucleotides Used for Renilla Luciferase Containing Constructs. 
aPolarity of the oligonucleotide relative to the positive strand of the construct.  Mutated bases are in bold and 
underlined.  Restriction sites are in bold. 
  
Oligonucleotide Pol.a Sequence (5’→3’) Purpose 
NgoMIV-T7-1 + GGGC GCC GGC TAA TAC GAC TCA CTA TAG GAT TGT GAG CGA TTT GC 
T7 prom +BCoV 
nt1 
5'UTR/RLUC-5' + GGC CCA CCC ATA GGT CAC AAT GGG ATC CGC TTC CAA GGT GTA CGA CC 
BCoV 5’UTR 
overlap with RLuc 
5'UTR/RLUC-3' - GGT CGT ACA CCT TGG AAG CGG ATC CCA TTG TGA CCT ATG GGT GGG CC 
BCoV 5’UTR 
overlap with RLuc 
3'UTR/RLUC-5' + GAA CGA GCA GAG ATC TAT CAA GCT TTA AGA GAA TGA ACC TTA TGT CG 
BCoV 3’UTR 
overlap with RLuc 
3'UTR/RLUC-3' - CGA CAT AAG GTT CAT TCT CTT AAA GCT TGA TAG ATC TCT GCT CGT TC 
BCoV 3’UTR 
overlap with RLuc 
sg7-3' - GGGC GGA TCC CAT CCT TAA AGT TTA G 5’UTR 77nt leader sequence 
BCov-396-3' - GCCC GGATCC ACA ATC CAC CAT CAC ATG A 5’ to include nsp 1 nts 211-396 
40nt-Δp(A)-5’ + GGGC AAGCTT TAA GAA TAC TCA GCT TGC  40nt 3’UTR 
40nt-Δp(A)-3’ - GGGC AAGCTT GCATGC ACGCGT  GCA CTC TAG AGT CG  40nt 3’UTR 
40nt-p(A)OVLP-5’ + GCAGGTCGACTCTAGAGTGCAAAAAAAAAAAAAAA 40nt  + p(A) (3’UTR only) 
40nt -p(A)OVLP-3’ - TTTTTTTTTTTTTTTGCACTCTAGAGTCGACCTGC 40nt  + p(A) (3’UTR only) 
40-p(A)OVLP 2-5’ + GAACGAGCAGAGATCTATCAAGCTTTAAGAATACTCAGCTTG 40nt  + p(A) 
40-p(A)OVLP 2-3’ - CAAGCTGAGTATTCTTAAAGCTTGATAGATCTCTGCTCGTTC 40nt  + p(A) 
FLIP 3'utr -5' + GGGC AAGCTT TAA GTG ATT CTT CCA ATT GG  Reversed BCoV 3’UTR 
FLIP 3'utr -3' - GCCC AAGCTT GCA TGC ACG CGT GAG AAT GAA CCT TAT GTC GGC 
Reversed BCoV 
3’UTR 
FLIP 3'utr –ovlp5' + CCGACATAAGGTTCATTCTCAAAAAAAAAAAAAAA FLIP  + p(A) 
FLIP 3'utr –ovlp3’' - TTTTTTTTTTTTTTTGAGAATGAACCTTATGTCGG FLIP  + p(A) 
SLoct ovlp5’ + GAACGAGCAGAGATCTATCAAGCTTTAATTGAAAGTTTTGTGTGGTAATG BSLoct 3’UTR 
SLoct ovlp3’ - CATTACCACACAAAACTTTCAATTAAAGCTTGATAGATCTCTGCTCGTTC BSLoct 3’UTR 
BSLpk ovlp5’ + ATAGCAGACTATAGATTAATTAGAAAAAAAAAAAAAAAAA BSLpk 3’UTR 
BSLpk ovlp3’ - TTTTTTTTTTTTTTTTTCTAATTAATCTATAGTCTGCTAT BSLpk 3’UTR 
m.uAUG-5' + CAC TCC CTG TAT TCT AGG CTT GTG GGC CTA GA uAUG to AGG 
m.uAUG-3' - TCT AGG CCC ACA AGC CTA GAA TAC AGG GAG TG uAUG to AGG 
m.124STOP-5' + GTG GGC GTA GAT TTT TCA TCG TGG TGT C A125C overlap 
m.124 STOP -3' - GAC ACC ACG ATG AAA AAT CTA CGC CCA C A125C overlap 
m.124/184  
STOP -5' + GGA CGT GTT GTA TCC TCG GCA GTG GC A185C overlap 
m.124/184 
STOP -3' - GCC ACT GCC GAG GAT ACA ACA CGT CC A185C overlap 
uORF-fusion-3' - GCCC GGATCC CCT TGT GAC CTG TGG GTG GGC CAC 
U202C,U212G 
overlap 
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Results  
Capped transcripts with genomic 5’ and 3’ UTR sequences show no translational advantage 
when translated in vitro. 
 For the purpose of observing the intrinsic effects of the viral UTR sequences on 
translation, we first analyzed the translation efficiency of a RLUC reporter construct with the 
BCoV 210nt 5’ UTR, 288nt 3’ UTR and a poly(A) tail, UTR210-288, and compared it to a control 
construct with putative optimal, nonviral UTRs.  The control construct, 5’OPT.-40, contains a 20 
nt 5’ UTR with an optimal Kozak sequence, a 40nt 3’ UTR (vector sequence) that is long 
enough so as to not sterically hinder translation, and a poly(A) tail (82, 150).  Transcripts were 
translated for 90 minutes and samples were taken at the indicated times.  Luciferase activity 
was measured and the results are presented as the average of at least three independent 
experiments.  Comparing the translation levels of capped transcripts of the viral wildtype 
construct UTR210-288 with the capped nonviral control 5’OPT.-40, reveals there is virtually no 
difference in luciferase activity (Fig. 3-2). Thus, it appears as though the viral 210nt 5’ UTR and 
288nt polyadenylated 3’ UTR are able to support translation levels equal to that of a much 
shorter 20nt 5’ UTR with an optimal translation context and a 40nt polyadenylated 3’ UTR.  
Therefore, capped transcripts with the viral UTRs do not appear to have a cis-acting 
translational advantage over an optimal RNA control, at least in the absence of viral proteins.   
 Because small differences in translation may be masked by the translational advantage 
given by the 5’ cap, uncapped RNAs were compared.  Translation levels of uncapped 
transcripts of the optimal control construct, 5’OPT-40, were 50% decreased compared to the 
translation levels of capped transcripts.  Interestingly, the translation levels of uncapped 
UTR210-288 were the same as the levels observed for capped UTR210-288 (Fig. 3-2).    These 
results indicate that translation levels of UTR210-288, which contains both the viral 5’ and 3’ 
UTRs are the same, regardless of whether or not the input RNA is capped or uncapped.  This 
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Figure 3-2.  Capped Transcripts With Genomic 5’ and 3’ UTR Sequences Show No 
Translational Advantage When Translated in vitro.   Translation levels of RNAs with both the 
viral 210nt 5’ and 288nt 3’ UTR (UTR210-288), only the viral 210nt 5’ UTR (UTR210-40), only 
the viral 288nt 3’ UTR (5’OPT.-288), or neither (5’OPT.-40). 
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result was unexpected, as it appears that cap-independent translation is as efficient as cap-
dependent translation of transcripts with both viral UTRs.  Following current translation models 
for naturally capped mRNAs, translation levels of the capped RNA should be increased 
compared to translation levels of the uncapped RNA (53), as demonstrated with 5’OPT.-40.  
Coronavirus RNAs are capped and thought to be translated via cap-dependent initiation and 
ribosome scanning (134, 135).  Thus, assuming coronavirus RNAs are translated via this 
mechanism, two questions can be asked; (i) are translation levels of capped RNA repressed, 
and (ii) are translation levels of uncapped RNA increased? 
Viral genomic 5’ and 3’ UTRs both contribute to the repression of cap-dependent translation. 
 To address these proposed questions, we examined translation levels of transcripts with 
differing combinations of 5’ and 3’ UTRs.  Reference basal levels of translation were established 
by translating uncapped transcripts.  Comparing translation levels of UTR210-288 with 5’OPT-
288, and UTR210-40, an increase in translation of capped transcripts was observed with both 
5’OPT-288 and UTR210-40 compared with translation levels of uncapped transcripts (Fig. 3-2).  
These results suggests that translation of capped 5’OPT.-288 and UTR210-40 are both more 
efficient than UTR210-288 and that by replacing one of the viral UTRs with a nonviral sequence, 
cap-dependent translation levels can be increased.  Therefore, cap-dependent translation 
appears to be repressed when both viral 5’ and 3’ UTRs are present.   
 The results of these experiments indicate there are elements within the viral 5’ and 3’ 
UTRs collectively contributing to an overall repression of cap-dependent translation.  
Furthermore, the results suggest that there may be a 5’-3’-end interaction that contributes to a 
mechanism of cap-dependent translation repression.  To more clearly understand the roles of 
the viral 5’ and 3’ UTRs in translation and how they may function together to repress cap-
dependent translation, the contributions of each UTR were analyzed separately.   
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Elements within the viral 3’ UTR contribute to a repression of cap-dependent translation.  
 From the above experiments, two effects were evident from the control 40nt 3’ UTR in 
the context of the genomic 210nt 5’ UTR:  (i) translation of capped UTR210-40 was increased 
compared to UTR210-288, (ii) translation of uncapped UTR210-40 was decreased compared to 
capped UTR210-40, indicating there was no repression of cap-dependent translation.  To 
determine if the length or an element within the 3’ UTR contributed to these effects, a construct 
with an equally long UTR was designed.  For this construct, UTR210-FLIP, the negative strand 
of the 3’ UTR replaced the wildtype UTR.  Translation levels of capped UTR210-FLIP were 
decreased by 20% compared to the levels of UTR210-288 at 90 minutes (p=0.023) (Fig. 3-3A).   
In addition, translation levels of capped UTR210-288 and UTR210-FLIP were both decreased 
approximately 50% at 90 minutes compared to UTR210-40 (p≤0.002) (Fig. 3-3A).  This 
indicates that the short 40nt 3’ UTR confers more efficient translation than either the viral 288 3’ 
UTR or FLIP 3’ UTR, and that the length of the 3’ UTR may negatively affect translation. 
However, translation levels of uncapped UTR210-FLIP were 30% decreased compared to the 
capped transcript, suggesting there was no repression of cap-dependent translation as 
observed with UTR210-288.  These results therefore indicate that the repression of cap-
dependent translation does not reside in the FLIP sequence and while the length of the 3’ UTR 
may contribute to lower translation levels, it does not contribute to the repression observed with 
the wildtype genomic 3’ UTR.  Hence, it is likely repression of cap-dependent translation is a 
function of the sequence or higher-order structures of the 3’ UTR.   
 To determine if the 288nt 3’ UTR sequence represses cap-dependent translation in the 
context of a non-viral 5’ UTR, the effects with different combinations of 5’ UTRs were tested.  In 
Figure 3-3B capped transcripts with the 5’OPT. 5’ UTR and three different 3’ UTRs are shown.   
Translation levels of capped 5’OPT.-288 were greater than 5’OPT.-40 and 5’OPT.-FLIP 
(p≤0.028, 90min.).  Therefore, the viral 288nt 3’ UTR appears to support increased translation 
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Figure 3-3.  The Viral 3’ UTR Does Not Independently Repress Cap-Dependent Translation  A.  Translation levels of 
transcripts with the viral 210nt 5’ UTR and five different 3’ UTRs (288nt viral UTR, 40nt control sequence, FLIP: negative strand 
of the 288nt viral UTR), SLoct (nts 1-172) viral 3’ UTR sequence, BSLpk (nts 173-288) viral 3’ UTR sequence.  B.  Translation 
levels of RNAs with the 5’OPT. UTR and three different 3’ UTRs.  C.  Translation levels of nonpolyadenylated RNAs.
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levels when paired with the nonviral optimal sequence 5’ UTR.  These data indicate that the 
viral 3’ UTR does not independently contribute to the observed repression of cap-dependent 
translation and supports a 5’-3’ UTR repressive interaction that may involve a specific element 
within the 3’ UTR. 
The 3’ UTR bulged stem-loop and adjacent pseudoknot contribute to a repression of cap-
dependent translation.     
 To identify the features in the 288nt 3’ UTR involved in repressing translation, the viral 3’ 
UTR was divided into two sections.  In addition to the poly(A) tail, two cis-acting replication 
elements have been identified within the viral 3’ UTR.  A bulged-stem-loop and adjacent 
pseudoknot (BSLpk) that likely function together is located immediately downstream of the 
coding region stop codon.  The second cis-acting stem-loop structure (SLoct) is located near the 
3’ UTR terminus and contains a conserved 8-mer sequence that is found in all known 
coronavirus 3’ UTRs (15).  To determine if one of these two higher-order structures was 
specifically responsible for the observed translation repression, each element was cloned 
separately with the viral 210nt 5’ UTR to yield constructs UTR210-SLoct (nts 1-172 from 3’ end) 
and UTR210-BSLpk (nts 173-288 from 3’ end).  The results show that translation levels of both 
transcripts were lower than UTR210-288 (Fig. 3-3A).  However, translation levels of capped and 
uncapped UTR210-BSLpk were equal, suggesting cap-dependent translation was repressed, 
potentially by the same mechanism observed with UTR210-288 (Fig. 3-3A).  Alternatively, 
translation levels of capped UTR210-SLoct were increased compared to uncapped transcripts, 
indicating cap-dependent translation was not repressed.  Therefore, the cis-acting bulged stem-
loop and pseudoknot structures may aid in cap-dependent translation repression. 
The observed repression of cap-dependent translation is independent of the 3’ poly(A) tail.   
 To eliminate the potential influence on translation from the 5’ cap-3’ poly(A) tail 
interaction and to look only at the influence of the UTRs, RNAs without poly(A) tails were tested.  
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Although the translation levels of the non-polyadenylated RNAs were lower, the overall trend 
remains the same (Fig. 3-3C, compare to Figure 3-2).  When both the viral 5’ and 3’ UTRs were 
present, (UTR210-288Δp(A)), translation levels were lower compared to when only one viral UTR 
was present (5’OPT.-288Δp(A), UTR210-40Δp(A)).  Furthermore, translation levels of capped and 
uncapped UTR210-288Δp(A) were equal, indicating cap-dependent translation was repressed 
independently of the 5’ cap-3’ poly(A) tail interaction (Fig. 3-3C).  This observation suggests 
there is a specific, 5’-3’ interaction that is responsible for the repression of cap-dependent 
translation and that it is independent of the 5’ cap-3’ poly(A) interaction.   
An uAUG in the 5’ UTR does not contribute to the repression of cap-dependent translation.   
 Regulatory elements have been found in the 5’ UTRs of mRNAs that may increase or 
decrease translation, typically at the rate-limiting step, translation initiation (63).  One cis 
element within the 5’ UTR that may attenuate translation is an upstream AUG (uAUG).  
Regulation of these elements can furthermore be dependent on interactions with the 3’ UTR 
(109). Ribosomes typically initiate translation at the first AUG and an uAUG can decrease 
translation initiation events of the main open reading frame because ribosomes instead initiate 
translation upstream of the main coding region (84). A single uAUG in virtually all coronaviruses 
and in the BCoV 5’ UTR is found at nucleotide 100 (Fig. 3-4A).  If translated, the open reading 
frame (uORF) would yield an eight amino acid peptide.  
 To determine if the uAUG was being used to initiate translation and therefore 
contributing to a repression of cap-dependent translation, it was necessary to extend the uORF 
coding region in order to detect the translation product.  Construct uORF fusion-288 was made 
by mutating the three in-frame stop codons at nucleotides 124, 184, and 202 to amino acid 
codons.  Also, the main 211 AUG was mutated to AGG (Fig. 3-4A, B).  With this RNA, initiation 
should only occur at the uAUG, making a slightly larger RLuc fusion protein.  The results show 
that translation levels of capped uORF fusion-288 were only 30% of capped UTR210-288 
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Figure 3-4.  An uAUG in the 5’ UTR Does Not Contribute to the Repression of Cap-
Dependent Translation.  A.  BCoV 5’ UTR.  The uAUG is within cis-acting SLIII and if 
translated would yield an 8aa peptide.  The uORF is in-frame with the main 211AUG.  There are 
two additional in-frame stop codons at nts 124 and 184.  B. Construct diagrams of mutant uAUG 
(m.uAUG-288) in which the uAUG has been changed to a non-start codon, AGG (U101G).  One 
additional mutation (G112C) was made to maintain the base pairing in the stem structure.  
uORF fusion-288 has the indicated codon changes in which the three native stop codons and 
main 211AUG have been mutated to amino acid codons, and translation initiation will only occur 
at the uAUG and yield an RLuc fusion translation product.  C.  Translation levels of capped 
UTR210-288 and m.uAUG-288 compared to uORF fusion-288.  D.  35S-Met.  translation 
products from capped RNA show translation from the uAUG is minimal and the major translation 
product is from a downstream coding region AUG. 
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levels at 90 minutes, indicating the uAUG is not used frequently (Fig. 3-4C).  In a second 
method of analysis, translation of these RNAs using 35S-Met and SDS-PAGE was done (Fig. 3-
4D).  Confirming the luciferase data, translation of uORF fusion-288 resulted in one light upper 
band which is representative of initiation from the uAUG.  A second band, the major translation 
product, represents translation from an AUG within the RLuc coding region.  Based on 
phosphorimager quantitation, the ratio of the bands representing translation from the uAUG and 
the coding region AUG, indicate the uAUG is used ~20% of the time.  These results show that 
the uAUG is used as a start codon, however, leaky scanning past the uAUG appears to occur 
most of the time. This may in part be due to the poor Kozak context of the uAUG. 
 In order to determine if the uAUG could have a regulatory effect on translation, a mutant 
construct was designed, (m.uAUG-288), in which the uAUG was changed to the non-start 
codon AGG (Fig. 3-4A, B).  In addition, since this codon is within a cis-acting stem-loop, one 
additional compensatory mutation was made to maintain the stem-loop structure as predicted by 
mfold.  As shown in Figure 3-4C and 3-4D, there was no change in translation levels of capped 
m.uAUG-288, compared to UTR210-288.  This result was surprising as it was expected that the 
uAUG would be a regulatory element since it is highly conserved and is found in all 
coronaviruses sequenced to date with only one exception (Brian, D.A., Gustin, K.M., 
unpublished data).  From these results it appears as though the uAUG is not a translation 
regulatory element due to its inefficient usage and therefore not likely to be involved in an 
overall repression of translation. 
Repression of cap-dependent translation by the 5’ UTR is localized to the 65 nucleotide viral 
leader sequence.  
   To further characterize the features of the 5’ UTR that contribute to the repression of 
cap-dependent translation, the 77nt 5’ UTR of subgenomic mRNA 7 (sg7-288) was tested and 
compared to UTR210-288. The first 65nt of sg7-288 and UTR210-288 are identical, called the 
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leader sequence, and present on all viral genomic and subgenomic messages (135).  
Translation levels of sg7-288 are consistent with those of UTR210-288, indicating there is no 
difference in translation between the 210nt and 77nt  5’ UTRs.  Interestingly, translation levels of 
capped and uncapped sg7-288 were also the same, indicating a similar cap-dependent 
translation phenomenon as observed with UTR210-288 (Fig. 3-5A).  Therefore, it appears that 
cap-dependent translation is also repressed when only a short 77nt viral 5’ UTR sequence is 
present with the viral 3’ UTR.  The observed effect on cap-dependent translation is thus 
localized to within the common 65nt viral leader sequence of the 5’ UTR.  As with the 210nt 
genomic 5’ UTR, there was no repression observed with the 40nt 3’ UTR and the 77nt 5’ UTR, 
(sg7-40), and translation levels of capped transcripts were ~30% increased compared to sg7-
288 at 90 minutes (Fig. 3-5A).  Furthermore, translation levels of capped sg7-40, were 
increased over levels of the uncapped transcript, supporting the observation that repression of 
cap-dependent translation is also dependent on the 3’ UTR as shown with the full length 210nt 
5’ UTR (Fig. 3-5A).   
 In addition, in the absence of the viral 3’ UTR, the 210nt 5’ UTR does not appear to 
negatively affect translation levels and may instead contain elements that enhance translation 
since translation levels of  capped UTR210-40 are increased compared to those of sg7-40 and 
5’OPT.-40 (Fig. 3-5B).  Because both UTR210-40 and sg7-40 share the viral leader sequence, 
the proposed enhancing elements may be within the downstream 5’ UTR sequence which 
contains cis-acting stem-loops III and IV.  These results indicate that the viral 5’ UTR does not 
independently repress cap-dependent translation levels and supports a 5’-3’ UTR interaction 
that is localized to within the viral leader sequence. 
Discussion 
 In this study we report the observation that in vitro and in the absence of viral proteins, a 
luciferase reporter RNA with the bovine coronavirus 5’ and 3’ UTRs does not display enhanced 
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Figure 3-5.  Cap-Dependent Translation Repression is Localized to Within the Viral 65 nt 
Leader Sequence.  A.  Translation levels of UTR210-288, sg7-288, and sg7-40.  B.  
Translation levels of transcripts in the absence of the viral 288nt 3’ UTR. 
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translation as a function of a 5’ cap structure.  Since the coronavirus genome and sgmRNAs are   
5’ capped and 3’ polyadenylated, it has been presumed that they utilize a cap-dependent 
ribosomal entry mechanism for translation initiation.  Comparisons with control constructs with 
nonviral UTRs demonstrated that the translational enhancement conferred via cap-dependent 
translation was repressed only in the presence of both viral UTRs.  Analyses mapped the 
repressive elements to the 65nt leader in the 5’ UTR and to the bulged stem-loop-pseudoknot 
structure in the 3’ UTR.  The significance of these findings are two-fold.  First, there must be a 
mechanistic explanation for repression.  Second, experiments addressing the influences of viral 
proteins on translation are necessary.   
 While an enhancement of translation via a 5’ cap-3’ poly(A) tail interaction is believed to 
occur during translation of naturally capped cellular mRNAs, additional interactions in the BCoV 
UTRs appear to have the opposite effect.  The mechanism through which the observed 
translation repression occurs could in theory involve RNA-RNA interactions between the UTRs.  
However no strong association or complementarity has been found based on sequence 
analysis.  Recently in MHV a direct 5’-3’ RNA interaction has been proposed to occur between 
bases in a stem-loop in the 5’ UTR and 3’ UTR terminal region based on the recovery of 5’ UTR 
mutant viruses with 3’ UTR second site suppressor mutations (98).  However, it is unclear if this 
region is representative of a true 5’-3’ interaction or if it could occur in BCoV.  Therefore, 
protein-protein interactions or RNA-protein interactions likely cause the observed translation 
suppression.  Since this study was performed in the absence of viral proteins, cellular proteins 
are the only potential mediators.    
 Translation regulation of this type could be virus or cell-mediated and control the rate at 
which viral proteins are produced.  Alternatively, repression of translation initiation could be a 
precursor to the switch from translation to genome replication which likely involves cellular 
proteins.  Cellular proteins have been found to bind to both the 5’ and 3’ UTRs.  Two cellular 
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proteins have been found to bind to the 5’ UTR of MHV, hnRNP Q3 and polypyrimidine tract-
binding protein (PTB) or hnRNP I (33, 96).  In addition, mitochondrial aconitase, three heat 
shock proteins, and hnRNP A1  have been shown to bind to the viral 3’ UTR (97, 113, 114).  
 The hnRNP family of proteins have been found to bind to the UTRs of RNA viruses and 
are involved in both translation and RNA synthesis (90).   Both hnRNP E (poly C-binding protein 
(PCBP)), and hnRNP C have been shown to be important for poliovirus (PV) RNA synthesis (4, 
22).  In addition hnRNP A1 is involved in hepatitis C virus (HCV) replication (79).  PTB has been 
shown to interact with RNA in poliovirus, hepatitis C virus, hepatitis A virus, HIV, and human T-
cell leukemia virus (90).  Although the significance of these interactions is not known in all 
cases, PTB has been shown to be necessary for IRES dependent translation in viruses such as 
PV and HCV (1, 62, 118). 
  In MHV, PTB-hnRNPA1 binding interactions have been proposed to circularize the 
genome and provide a circular closed loop for replication (70).  These two components of a pre-
mRNA splicing complex were initially co-purified and therefore may together form part of a viral 
RNA transcription complex (90).  Depletion of PTB or hnRNPQ3 has been shown to be 
inconsequential in cap-dependent translation of an MHV reporter construct, indicating that these 
proteins do not function in translation (32, 33).  However, overexpression or depletion of these 
factors resulted in altered growth kinetics in MHV implicating a role in RNA synthesis (32, 139).   
 Because both PTB and hnRNPA1 bind to the 5’ and 3’ UTRs respectively, and have 
been shown to interact with each other (70), they could be suppressing cap-dependent 
translation by blocking access to the 5’ UTR.  In this scenario, cap-dependent translation may 
be inhibited through the association of protein factors necessary for RNA transcription.  
However, in the absence of viral proteins, as in our experiments, there is no transcription (Fig. 
3-6).  This model is applicable to both the genomic and subgenomic RNAs since translation was 
suppressed with only the 77nt 5’ UTR.  Based on our data we can speculate that in vitro and in 
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Figure 3-6.  Translation Repression Model.   Translation of coronaviruses is believed to occur by the canonical cap-dependent 
translation initiation via a closed loop formed through interactions with the 5’ UTR cap binding complex eIF4F and PABP.  
However, an additional 5’-3’ UTR interaction formed through interactions with cellular proteins (possibly proteins involved in RNA 
synthesis) could result in inefficient recruitment or binding of initiation factors, ribosome loading, or ribosome scanning.  In the 
absence of this interaction, there is no repression. 
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the absence of viral proteins, all viral RNAs are in an intermediate complex conformation and 
that additional viral protein factors involved in either promoting translation or the initiation of 
negative strand RNA synthesis are missing. 
 In infected cells, viral proteins also likely differentially mediate translation of both the 
genomic RNA and the sgmRNAs.  It has previously been reported that in infected cells the N 
protein enhances translation of a reporter construct with the MHV UTRs (149).  Also, in BCoV 
infected cells, translation of transfected RNAs with the 210nt 5’ UTR were decreased compared 
to RNAs with only the 77nt sgmRNA 7 5’ UTR (135).  These data indicate that not only do viral 
proteins regulate translation, but that in the presence of viral proteins, mRNA species with 
different 5’ UTRs may be regulated differently.  Viral proteins could upregulate or downregulate 
translation through interactions directly with the RNA or through interactions with cellular 
proteins depending on the stage of replication.   
 This study provides a detailed look at the effects of the viral UTRs in coronavirus 
translation.  In this limited in vitro system we observed no evidence of a cis-acting translational 
advantage that might be necessary for a productive virus infection, but instead found seemingly 
repressed levels of cap-dependent translation.   The proposed model suggests the repressed 
translation could be indicative of an intermediate stage in virus replication.  However, further 
studies will be necessary to investigate the mechanism.  Our initial observations led us to pose 
two questions, (i) is translation of capped transcripts repressed, or (ii) is translation of uncapped 
transcripts enhanced.  Although we addressed the former question, the latter remains 
unanswered and intriguing.  During coronavirus infection, synthesis of viral proteins continues 
even after host protein synthesis has been inhibited by the viral infection (10, 64, 127).  
Therefore we can ask: if in an environment in which cap-dependent translation is inhibited, is 
there a secondary mechanism through which coronavirus RNAs are translated? There are 
reports of secondary mechanisms of translation when cap-dependent translation is inhibited 
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including IRES mediated translation of cellular RNAs and an apparent novel mechanism that 
involves a 5’-3’ UTR interaction in dengue virus RNAs which circumvents the need for eIF4E 
(48, 104).  In addition there is precedent for alternate translation mechanisms in coronaviruses, 
including reports of IRES translation of coronavirus multicistronic ORFs, ORF 3c in IBV, ORF 5b 
in MHV, and ORF 3b in TGEV (100, 120, 151).  Also, a weak IRES has been identified in the 5’ 
UTR of the IBV genome (101).  Future studies will be necessary to investigate this possibility. 
 Overall, the underlying mechanism of translation and its regulation in coronaviruses 
remains elusive.  Future studies are needed to address the influence of viral proteins on 
translation and regulation.  Furthermore, it is necessary to determine if the observed repression 
of cap-dependent translation occurs in vivo and if there is a secondary mechanism for the 
preferential translation of viral RNAs when cap-dependent translation is inhibited.  Also, since 
each viral UTR was shown to enhance translation, identification of translation enhancer 
elements within the viral UTRs would provide useful information regarding translation regulation 
in coronaviruses.   
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Chapter IV.  Coronavirus Nsp 1 Bioinformatic Analysis 
 
Introduction 
 Coronaviruses have been isolated from birds, mammals, and humans.  Most coronavirus 
infections are associated with gastroenteric and respiratory infections (89, 165).  Severe acute 
respiratory syndrome coronavirus (SARS-CoV) however, causes severe respiratory disease and 
the 2003 outbreak resulted in an ~10% mortality rate worldwide (24).  Since the emergence of 
SARS-CoV, the number of new coronaviruses and coronavirus isolates has dramatically 
increased.  Coronaviruses have been classified into three groups based on antigenic 
differences and genome sequence (106).  More recently further classification has divided 
groups into subgroups.  Group 2 coronaviruses are perhaps the most studied of the three 
groups of coronaviruses, partially due to the fact that SARS-CoV is a member of this group.  
Group 2 members bovine coronavirus (BCoV) along with mouse hepatitis coronavirus (MHV) 
have been subdivided into group 2a, and SARS-CoV has been subdivided into group 2b (161, 
169).  More recent group 2 members have been placed in subgroups 2c and 2d and currently 
include only bat coronaviruses (169).  
 All coronavirus nonstructural proteins are translated and cleaved from a large 
polyprotein encoded in the 5’-proximal two-thirds of the ~30kb genome.  In group 2 viruses 
there are sixteen predicted protein products from the ORF 1a/1b polyprotein.  The first 
nonstructural protein (nsp 1) is cleaved cotranslationally almost immediately after it is translated 
(38).  This protein is approximately 28kDa in group 2a coronaviruses and is also referred to as 
p28.  In SARS-CoV and group 2c and 2d the protein is smaller, approximately 20kDa.   
 A definitive function for nsp 1 in virus replication has not been determined but it has 
been shown to be required for replication.  It is known that the N-terminal part of the coding 
region has a separate requirement for both the RNA secondary structure and the translation 
product (Chapter II) (18, 20). Two cis-acting stem-loops are known to exist within this region of 
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nsp 1 in BCoV and are required for DI RNA replication (Chapter II) (20).    In MHV, deletion of 
nsp 1 N-terminal segments or N-terminal alanine mutagenesis using a full length infectious 
clone results in impaired or no virus replication (18).  Considering the requirement for the 
translation product, replication of BCoV DI RNA is inhibited when the nsp 1 start codon is 
mutated to a stop codon or the coding sequence is altered by the introduction of a frameshift 
mutation (20).  It is postulated that nsp 1 is part of the viral replication complex, as it was found 
to associate with viral RNA and viral proteins that include the helicase, RdRp, nucleocapsid, and 
matrix proteins (19). Nsp 1 has furthermore been shown to directly bind two viral nonstructural 
proteins nsp 7 and nsp 10 (19).  The functions of these two nonstructural proteins in virus 
replication are not known.   
 Although there is a replication requirement for nsp 1 and it interacts with both RNA and 
other proteins, the significance of these interactions and how they function in virus replication is 
unknown.  In MHV and SARS-CoV, nsp 1 has recently been shown to affect cellular processes 
including cell cycle arrest, mRNA decay and translation shutoff (78, 115, 164, 177).  
Furthermore in BCoV, p28 overexpression negatively affects viral RNA levels and could 
potentially affect cellular levels as well, implying a conserved function may exist between these 
viral proteins (Chapter II).  It is possible these observed effects are due to interactions between 
nsp 1 and other unidentified factors. 
 Due to the close relationship between group 2a coronaviruses BCoV and MHV, the cis-
acting function of the nsp 1 5’-terminal region and protein functions of nsp 1 are likely conserved 
elements.  However, it is not known if the more divergent SARS-CoV nsp 1 or other coronavirus 
nsp 1 sequences share some or all of these elements.  In this analysis, the predicted secondary 
structures and the nsp 1 amino acid sequences have been compared in order to characterize 
and identify elements similar to those in BCoV nsp 1.  Analysis of the secondary structure of the 
nsp 1 5’ terminal regions from selected group 2 coronaviruses showed most to be BCoV like 
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and revealed SARS-CoV to be more group 1 like.  Amino acid alignments also showed most 
sequences having high similarity to BCoV.  However, SARS-CoV showed some similarities with 
group 1 coronaviruses.  In addition, although RNA and protein binding have been 
experimentally demonstrated for BCoV and MHV nsp 1, respectively, no specific binding 
domains have been determined.  Therefore, potential binding motifs have been predicted by 
bioinformatic analysis of BCoV nsp 1.  A total of three putative RNA and protein interaction 
motifs have been predicted in BCoV and may be partially conserved in MHV.  Only one of these 
regions may be conserved among BCoV, MHV, and SARS-CoV, and could potentially 
contribute to a conserved interaction domain and possibly a conserved functional domain. 
Materials and Methods 
 Genbank Accession Numbers.  BCoV #U00735, HECV-4408 #AF523844, HCoV-
OC43 #NC_005147, PHEV #DQ011855, ECoV #NC_010327, MHV A59 #AY700211, SARS-
CoV#AY291315, BatSARS-HKU3-1 #DQ022305, BatCoV HKU4-1 #EF065505, BatCoV HKU9-
1 #EF065513, FCoV #NC_007025, TGEV #NC_002306, HCoV-229E #AF304460, PEDV 
#NC_003436 
 RNA structure predictions.  Mfold (http://mfold.bioinfo.rpi.edu/) was used to predict 
RNA secondary structures (107, 176). 
 Bioinformatics.  Nsp 1 amino acid sequence alignments and trees were constructed 
using Vector NTI Suite 8 (Invitrogen) Align X.  Phylogenetic trees were calculated from the 
multiple alignment by the Neighbor-Joining method (Saitou and Nei) (131).  Distance values 
representing the degree of divergence between sequences are shown in parentheses.  Protein 
binding domains were predicted with the SMART database (http://smart.embl-heidelberg.de/)   
(95, 133) using the full length p28 sequence as well as ~100 amino acid segments.  The 
putative binding domains were then used for PSI-BLAST (Position-Specific Iterated BLAST) 
(http://blast.ncbi.nlm.nih.gov/Blast.cgi). (3, 146).  PSI-BLAST iterations were done until a non-
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coronavirus match was found.  This sequence was then used in SMART to determine if the 
same domains were predicted as in BCoV. 1.  For BCoV p28 35-75: Physcomitrella patens  
(EDQ51842) was identified and SMART identified putative binding domains including zinc 
fingers.  2.  For BCoV p28 100-160:  Burkholderia pseudomallei  (Genbank #ZP_02403227) 
was identified and SMART identified putative protein binding domain.  3.  For BCoV p28 90-190:  
Polaribacter dokdonensis (EAQ41748) was identified and SMART identified a transmembrane 
domain.  No matches were found for BCoV p28 190-246 (Appendix III).  Transmembrane 
domains were predicted using Tmpred. Scores above 500 are significant (Appendix III) 
(http://www.ch.embnet.org/software/TMPRED_form.html) (65). 
Results  
RNA Secondary Structure 
 In BCoV, stem-loops V and VI in the immediate nsp 1 coding region are necessary for DI 
RNA replication (Chapter II) (20).  These structures have been confirmed by RNase enzyme 
probing and disruption of either stem-loop structure results in a loss of DI RNA replication 
(Chapter II) (20).  The secondary structures of the nsp 1 5’-terminal cis-acting region of group 
2a viruses such as MHV, human enteric coronavirus HECV 4408, human coronavirus HCoV-
OC43, and porcine hemagglutinating encephalomyelitis virus (PHEV) are all predicted by mfold  
to be similar to that for BCoV (nucleotide sequence identity ≥60%), with an elongated stem-loop 
(SLV) downstream of the ORF 1a start codon that is immediately followed by a shorter stem-
loop (SLVI) (Fig. 4-1), BCoV and MHV shown).  Although the cis-replication functions of these 
elements in all group 2a coronaviruses have not been confirmed, based on sequence identity 
and secondary structure predictions, it is expected that these regions will function as cis-
replication elements as shown in BCoV (sequence alignment shown in Appendix III, Figure A3-
1A).  
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Figure 4-1.  5’-Terminal nsp 1 Secondary Structure mfold Predictions for Group 1 and 
Group 2 Coronaviruses.  Predicted secondary structures of group 1 TGEV and HCoV229E, 
group 2b SARS-CoV and group 2a BCoV and MHV.  The secondary structures of SLV and SLVI 
in BCoV have been confirmed by RNase probing. 
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 Group 2b member SARS-CoV is predicted to have three stem-loops within the 5’-
terminal nsp 1 coding region (Fig. 4-1).  Although SARS-CoV has been assigned to group 2, 
these predicted secondary structures appear more similar those in group 1 coronaviruses.  The 
nsp 1 sequence of group 1a FCoV and TGEV and group 1b members HCoV-229E and PEDV, 
are all predicted to have similar structures in the 5’-terminal nsp 1 coding region, a short stem-
loop followed by an elongated stem-loop (Fig. 4-1, TGEV and HCoV-229E shown).  The 
predicted stem-loops in SARS-CoV follow this arrangement with one additional upstream stem-
loop structure (sequence alignment shown in Appendix III, Figure A3-1B).  The predicted 
secondary structures of group 2c and 2d sequences are different from both group 1 and group 2 
and are not predicted to have similar stem-loop structures in the 5’ terminal nsp 1 region (data 
not shown).    
  Interestingly, the SARS-CoV predicted stem-loop arrangement is more similar to the 
predicted structures in the 5’ terminal nsp 1 sequences of group 1 coronaviruses.  This is 
intriguing because stem-loop IV within the 5’ UTR of SARS-CoV has also been predicted to be 
more similar to group 1 coronaviruses (130).  This mix of sequence identities may reflect the 
recombinant origin of SARS-CoV and represent a link between nsp 1 of group 1 and group 2 
coronaviruses. 
Nsp 1 Amino Acid Sequence 
 To analyze the nsp 1 amino acid sequences of the coronaviruses of interest, the entire 
nsp 1 coding regions were aligned and the results are presented as the percentage of similar 
residues.  A sequence alignment and phylogenetic tree of group 2 coronavirus nsp 1 amino 
acids is shown in Figure 4-2 and shows that HCoV-OC43, PHEV and HCoV-4408 are BCoV like 
and are more than 95% similar while equine coronavirus (ECoV) is approximately 75% similar.  
MHV is also closely related and approximately 60% similar with BCoV, while the more distant 
SARS-CoV is only 24% similar (Fig. 4-2).  Bat-SARs HKU3-1  nsp 1 sequence is virtually 
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Figure 4-2.  Group 2 Coronavirus nsp 1 Amino Acid Alignment and Phylogenetic Tree.  
Neighbor-Joining tree distance scores are shown in parentheses.  Conserved LRKxGxKG 
region is boxed. 
 BCoV U00735 nsp1 (0.0010)
HECV 4408 AF523848 nsp1 (0.0071)
PHEV DQ011855 nsp1 (0.0125)
HCoV-OC43 NC_005147 nsp1 (0.0293)
Equine CoV NC_010327 nsp1 (0.1747)
MHV A59 AY700211 nsp1 (0.0231)
MHV-JHM NC_006852 nsp1 (0.0174)
SARS AY 291315nsp1 (0.0102)
Bat-SARS CoV DQ022305 nsp1 (0.0121)
Bat CoV  HKU4-1  EF065505 nsp1 (0.4522)
Bat CoV HKU9-1  EF065513 nsp1 (0.4665)
2a
2b
2c
2d
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            BCoV U00735 nsp1    (1) MSKINKYGLELHWAPEFPWMFEDAEEKLDNPSSSEVDIVCSTTAQKLETGGICPENHVMVDCRRLLKQEC
     HECV-4408 AF523848 nsp1    (1) MSKINKYGLELHWAPEFPWMFEDAEEKLDNPSSSEVDIVCSTTAQKLETGGICPENHVMVDCRRLLKQEC
          PHEV DQ011855 nsp1    (1) MSKINKYGLELHWAPEFPWMFEDAEEKLDNPSSSEVDIVCSTTAQKLETGGICPENHVMVDCRRLLKQEC
    HCoV-OC43 NC_005147 nsp1    (1) MSKINKYGLELHWAPEFPWMFEDAEEKLDNPSSSEVDMICSTTAQKLETDGICPENHVMVDCRRLLKQEC
   Equine CoV NC_010327 nsp1    (1) MAKINKYGLDLQWAPEFPWMFEDTEEKLDNPSGSEVGIICPTTAQELGTCRITFENHVMVDCRRLI-QEG
       MHV A59 AY700211 nsp1    (1) MAKMGKYGLGFKWAPEFPWMLPNASEKLGNPERSEEDGFCPSAAQEPKVKGKTLVNHVRVNCSRLPALEC
      MHV-JHM NC_006852 nsp1    (1) MAKMGKYGLGFKWAPEFPWMLPNASEKLGNPERSEEDGFCPSAAQEPKVKGKTLVNHVRVDCSRLPALEC
          SARS AY291315 nsp1    (1) --------------------------------------------MESLVLGVNEKTHVQLSLPVLQ----
  Bat-SARS CoV DQ022305 nsp1    (1) --------------------------------------------MESLVLGVNEKTHVQLSLPVLQ----
 BatCoV HKU4-1 EF065505 nsp1    (1) ----------------------------------------MLSKASVTTQGARGKYRAELYNEKRSDHVA
 BatCoV HKU9-1 EF065513 nsp1    (1) ---------------------------------------------------------------------M
                                    71                                                                 140
            BCoV U00735 nsp1   (71) CVQSSLIREIVMNTRPYDLEVLLQDALQSREAVLVTPPLGMSLEACYVRGCNPNGWTMGLFRRRSVCNTG
     HECV-4408 AF523848 nsp1   (71) CVQSSLIREIVMNTRPYDLEVLLQDALQSREAVLVTPPLGMSLEACYVRGCNPNGWTMGLFRRRSVCNTG
          PHEV DQ011855 nsp1   (71) CVQSSLIREIVMNTRPYDLEVLLQDALQSREAVLVTPPLGMSLEACYVRGCNPNGWTMGLFRRRSVCNTG
    HCoV-OC43 NC_005147 nsp1   (71) CVQSSLIREIVMNASPYDLEVLLQDALQSREAVLVTTPLGMSLEACYVRGCNPKGWTMGLFRRRSVCNTG
   Equine CoV NC_010327 nsp1   (70) CVQSNLIREIKMNTRPYDMDRVIQDALLSREAVLIPPPRRLSIETCYKWGCCPQGWAMGLFRRCSTCY-G
       MHV A59 AY700211 nsp1   (71) CVQSAIIRDIFVDEDPQKVEASTMMALQFGSAVLVKPSKRLSIQAWTNLGVLPKTAAMGLFKRVCLCNTR
      MHV-JHM NC_006852 nsp1   (71) CVQSAIIRDIFVDEDPQKVEASTMMALQFGSAVLVKPSKRLSVQAWAKLGVLPKTPAMGLFKRFCLCNTR
          SARS AY291315 nsp1   (23) ----------VRDVLVRGFGDSVEEALSEAREHLKNGTCGLVELEKGVLPQLEQPYVFIKRSDALSTNHG
  Bat-SARS CoV DQ022305 nsp1   (23) ----------VRDVLVRGFGDSVEEALSEAREHLKNGTCGLVELEKGVLPQLEQPYVFIKRSDALSTNHG
 BatCoV HKU4-1 EF065505 nsp1   (31) CTVPLCDTDDMACKLTPWFEDGETAFNQVSSILKEKGKILFVPMHMQRAMKFLPGPRVYLVERLTGGMLS
 BatCoV HKU9-1 EF065513 nsp1    (2) VVTTLKWCDPFANPNVTGWDIPIEEALEYAKQQLRTPEPQLVFVPYY----LSHAPGISGDRVVITDSIW
                                    141                                                                210
            BCoV U00735 nsp1  (141) RCAVNKHVAYQLYMIDPAGVCFGAGQFVGWVIPLAFMPVQSRKFIVPWVMYLRKCGEKGAYNKDH-KRGG
     HECV-4408 AF523848 nsp1  (141) RCAVNKHVAYQLYMIDPAGVCFGAGQFVGWVIPLAFMPVQSRRFIVPWVMYLRKCGEKGAYNKDH-KRVG
          PHEV DQ011855 nsp1  (141) RCAVNKHVAYQLYMIDPAGVCFGAGQLVGWVIPLAFMPAQSRKFIVPWVMYLRKCGDKGAYNKDH-KRGG
    HCoV-OC43 NC_005147 nsp1  (141) RCTVNKHVAYQLYMIDPAGVCLGAGQFVGWVIPLAFMPVQSRKFIVPWVMYLRKRGEKGAYNKDH-GRGG
   Equine CoV NC_010327 nsp1  (139) GCDVNSHVAYQLFLIDPQGCCLGAGNFVGWVVPLAKLSKEAQAKTVPWTMWLRKRGEKGAYNKYH-KLDF
       MHV A59 AY700211 nsp1  (141) ECSCDAHVAFHLFTVQPDGVCLGNGRFIGWFVPVTAIPEYAKQWLQPWSILLRKGGNKGSVTSGHFRRAV
      MHV-JHM NC_006852 nsp1  (141) ECVCDAHVAFQLFTVQPDGVCLGNGRFIGWFVPVTAIPEYAKQWLQPWSILLRKGGNKGSVTSGHFRRAV
          SARS AY291315 nsp1   (83) HKVVELVAEMDGIQYGRSGITLG-------VL----VPHVGETPIAYRNVLLRKNGNKGAGGHSYGIDLK
  Bat-SARS CoV DQ022305 nsp1   (83) HKVVELVAELDGIQFGRSGITLG--------V---LVPHVGETPIAYRNVLLRKNGNKGAGGHSFGIDLK
 BatCoV HKU4-1 EF065505 nsp1  (101) KHFLVNQLAYKDQVGAAMMRTTLNAKPLGMFF-----PYDSSLETGEYTFLLRKNGLGGQLFRER-----
 BatCoV HKU9-1 EF065513 nsp1   (68) YATNFGWQPIRELAMDKDGVRYGRGGTHGVLLPMQDPSFIMGDIDIQIRKYGIGANSPPDVLPLWDGFSD
                                    211                                  250 
            BCoV U00735 nsp1  (210) FEHVYNFKVEDAYDLVHDEPKGKFSKKAYALIRGYRG--- 
     HECV-4408 AF523848 nsp1  (210) FEHVYNFKVEDAYDLVHDEPKGKFSKKAYALIRGYRG--- 
          PHEV DQ011855 nsp1  (210) FEHVYNFKVEDAYDQVHDEPKGKFSKKAYALIRGYRG--- 
    HCoV-OC43 NC_005147 nsp1  (210) FGHVYDFKVEDAYDQVHDEPKGKFSKKAYALIRGYRG--- 
   Equine CoV NC_010327 nsp1  (208) DDEVCDVLLERAYDSVLDDPKGKFSAKAFALLRSYRG--- 
       MHV A59 AY700211 nsp1  (211) TMPVYDFNVEDACEEVHLNPKGKYSCKAYALLKGYRG--- 
      MHV-JHM NC_006852 nsp1  (211) TMPVYDFNVEDACEEVHLNPRGKYSCKAYALLRGYRG--- 
          SARS AY291315 nsp1  (142) SYDLGDELGTDPIEDYEQNWNTKHGSGALRELTRELNGG- 
       BatSARS DQ022305 nsp1  (142) SYDLGDELGTDPIEDYEQNWNTKHGSGALRELTRELNGG- 
 BatCoV HKU4-1 EF065505 nsp1  (161) PWDRKETPYVEILDDLEADPTGKYSQNLLKKLIGG----- 
 BatCoV HKU9-1 EF065513 nsp1  (138) PGPDVGPYLDFPDNCCPTKPKAKRGGDVYLSDQYGFDNNG 
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identical to the SARS-CoV sequence (98% identity) (Fig. 4-2).  Group 2c and 2d bat 
coronaviruses are approximately 30% similar to each other and are more closely related to 
SARS-CoV than group 2a with 30% similarity (Fig. 4-2).  One region of amino acids, 
LRKxGxKG, (BCoV aa 192-199, SARS-CoV, aa 123-130), is conserved among all group 2 
coronaviruses analyzed except BatCoV 4-1 which has the sequence LRKxGxGG and BatCoV 
9-1 which does not have this sequence at all (Fig. 4-2).  This region consists primarily of 
charged residues and was mentioned by Almeida, et.al, as a potential interaction domain (2).    
 A phylogenetic tree of nsp 1 sequences from group 1 and group 2 coronaviruses is 
shown in Figure 4-3 (alignment shown in Appendix III, Figure A3-2).  Group 1a members 
including FCoV and TGEV have nsp 1 sequences that are 94% similar.  HCoV229E and PEDV, 
both group 1b members have nsp 1 sequences that are 64% similar.  Interestingly, as observed 
with the nsp 1  RNA secondary structure predictions, SARS-CoV nsp 1 amino acid sequence is 
both group 2-like and group 1-like with 24% similarity to group 2a BCoV and 21% similarity to 
group 1a FCoV (Fig. 4-3).  This apparent intergroup relationship may provide insight into both 
the origin and conserved functional properties of the nsp 1 proteins.   
Predicted Binding Motifs in BCoV Nsp 1 
 In BCoV and MHV, nsp 1 has been shown to interact with both viral RNA and proteins.  
In addition, experimental data suggests a conserved function may exist among nsp 1 proteins 
(30, 78, 115, 164, 177).  However, potential RNA or protein interaction regions through which 
nsp 1 may exert its function(s) have not been identified.  Bioinformatic analysis of BCoV nsp 1 
using the SMART domain prediction database (95, 133), has revealed potential binding motifs 
(Table 4-1).  A comparison with nsp 1 in MHV and SARS-CoV sequences reveals potential 
conservation with MHV but less so with SARS-CoV.   
 A domain search using SMART with the BCoV nsp 1 sequence identified three potential 
binding regions.   No interaction domains were confidently predicted, but all 
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SARS-CoV nsp 1 is group 2 like 
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Figure 4-3.  Phylogenetic Tree of Group 1 and Group 2 Coronaviruses.  Neighbor-Joining 
tree distance scores are shown in parentheses.  SARS-CoV nsp 1 sequence is approximately 
20% similar to both group 2 and group 1 coronaviruses. 
BCoV U00735 nsp1 (0.2699)
MHV AY700211 nsp1 (0.2667)
Bat-SARS CoV DQ022305 nsp1 (0.0087)
SARS AY 291315nsp1 (0.0079)
Bat CoV  HKU4-1  EF065505 nsp1 (0.4338)
Bat CoV HKU9-1  EF065513 nsp1 (0.4395)
FCoV NC_007025nsp1 (0.0291)
TGEV NC_002306 nsp 1 (0.0357)
HCoV 229E AF304460 nsp1 (0.2305)
PEDV NC_003436 nsp1 (0.2465)
2c
2d
2b
2a
1a
1b
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BCoV nsp1    (1) MSKINKYGLELHWAPEFPWMFEDAEEKLDNPSSSEVDIVCSTTAQKLETGGICPENHVMVDCRRLLKQEC
 MHV nsp1    (1) MAKMGKYGLGFKWAPEFPWMLPNASEKLGNPERSEEDGFCPSAAQEPKVKGKTLVNHVRVNCSRLPALEC
SARS nsp1    (1) --------------------------------------------MESLVLGVNEKTHVQLSLPVLQVRDV
                 71                                                                 140
BCoV nsp1   (71) CVQSSLIREIVMNTRPYDLEVLLQDALQSREAVLVTPPLGMSLEACYVRGCNPNGWTMGLFRRRSVCNTG
 MHV nsp1   (71) CVQSAIIRDIFVDEDPQKVEASTMMALQFGSAVLVKPSKRLSIQAWTNLGVLPKTAAMGLFKRVCLCNTR
SARS nsp1   (27) LVR-G------FGDSVEEALSEAREHLKNGTCGLVELEK----------GVLPQLEQPYVFIKR----SD
                 141                                                                210
BCoV nsp1  (141) RCAVNKHVAYQLYMIDPAGVCFGAGQFVGWVIPLAFMPVQSRKFIVPWVMYLRKCGEKGAYNKDHKR-GG
 MHV nsp1  (141) ECSCDAHVAFHLFTVQPDGVCLGNGRFIGWFVPVTAIPEYAKQWLQPWSILLRKGGNKGSVTSGHFRRAV
SARS nsp1   (76) ALSTNHGHKVVELVAEMDGIQYGRS----GITLGVLVPHVGETPIAYRNVLLRKNGNKGAGGHSYGIDLK
                 211                                 249 
BCoV nsp1  (210) FEHVYNFKVEDAYDLVHDEPKGKFSKKAYALIRGYRG-- 
 MHV nsp1  (211) TMPVYDFNVEDACEEVHLNPKGKYSCKAYALLKGYRG-- 
SARS nsp1  (142) SYDLGDELGTDPIEDYEQNWNTKHGSGALRELTRELNGG 
                 1                                                                   70
FCoV nsp1    (1) MSSKQFKILVNEDYQVNVPSLPFRDALQ------------EIKYCYRNGFDGYVFVPEYRRDLVDCNRKD
TGEV nsp1    (1) MSSKQFKILVNEDYQVNVPSLPIRDVLQ------------EIKYCYRNGFEGYVFVPEYCRDLVDCDRKD
SARS nsp1    (1) MESLVLGVNEKTHVQLSLPVLQVRDVLVRGFGDSVEEALSEAREHLKNGTCGLVELEKGVLPQLEQPYVF
                 71                                                                 140
FCoV nsp1   (59) HYVIGVLGNGISDLKPVLLTEPSVMLQG----------------------FIVRANCN----GVLEDFDL
TGEV nsp1   (59) HYVIGVLGNGVSDLKPVLLTEPSVMLQG----------------------FIVRANCN----GVLEDFDL
SARS nsp1   (71) IKRSDALSTNHGHKVVELVAEMDGIQYGRSGITLGVLVPHVGETPIAYRNVLLRKNGNKGAGGHSYGIDL
                 141                                  180 
FCoV nsp1  (103) KFARTGNG-------------------------------- 
TGEV nsp1  (103) KIARTG---------------------------------- 
SARS nsp1  (141) KSYDLGDELGTDPIEDYEQNWNTKHGSGALRELTRELNGG 
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Table 4-1.  Putative Motifs in BCoV nsp 1 as Determined by SMART. 
 
Name Aa  *E-Value Description 
Putative Motif I  
 
AN1 ZnF 
 
40 
 
67 
 
1.92e+02 
 
Zinc finger; involved in protein binding 
 
DED 15 95 2.03e+02 Death effector domain; involved in protein binding  
C2HC ZnF 52 64 1.12e+03 Zinc finger; found in the Nucleocapsid protein of retroviruses and 
eukaryotic RNA/ssDNA binding proteins. 
C4 ZnF 34 79 2.44e+03 Zinc finger; involved in DNA-binding. 
Zpr1-type ZnF 51 165 4.24e+03 ZPR1-type zinc finger domain; involved in protein binding 
Putative Motif II  
Thaumatin  106 241 2.71e+01 Primarily in plants; involved in pathogenesis; possible inhibitor 
EGF Lam 115 161 1.27e+03 Laminin-type epidermal growth factor-like domain; binds 
components of basement membranes 
Kringle  114 144 1.50e+03 Protein binding domain found in serine proteases  
Bowman-Birk 120 161 1.99e+03 Primarily in plants;  found in serine protease inhibitors 
Putative Motif III  
 
4.1m 
 
190 
 
208 
 
5.95e+02 
 
Putative band 4.1 homologues' binding motif; Found in 
neurexins, syndecans and glycophorin C intracellular C-termini.  
* E-value=score representing the probability that two sequences are matched by chance.  A lower number indicates 
higher similarity. 
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matches with above threshold E-values fit within three regions of the nsp 1 sequence (Fig. 4-4).  
Consistent with this data, a PSI-BLAST search using the putative motifs identified non-
coronavirus sequences that produced similar SMART hits.  However, because all hits are above 
levels considered significant, nsp 1 most likely contains novel interaction domains that need to 
be experimentally defined.   
 An N-terminal motif located between amino acids S34 and S75 has identity to five 
different protein and RNA binding domains.  Four are zinc finger domains, two of which are 
known to be protein binding zinc fingers and two are nucleotide binding domains (Table 4-1).  
Analysis of MHV nsp 1 sequence also reveals identity to a nucleic acid binding zinc-finger 
domain in the same region (Fig. 4-4 and data not shown).  In BCoV this region contains five 
cysteine residues, four of which are conserved in MHV, and a conserved histidine residue, 
which could collectively make up a binding motif (Fig. 4-4) (21, 60).  Since it is known from 
experimental data that BCoV nsp 1 is an RNA binding protein (Chapter II), this proposed N-
terminal region is therefore a good candidate for the identified RNA binding interactions with the 
cis-acting elements in the viral UTRs and may also be conserved in MHV.  Also, this domain is 
within the N-terminal region of the protein necessary for efficient virus replication, suggesting 
one function of nsp 1 in replication may require binding to viral RNA.  Alternatively, analysis of 
SARS-CoV nsp 1 did not find any potential binding motif in this region and sequence 
conservation with BCoV and MHV within this region is low (data not shown and Fig. 4-3). 
 The second region found to be a potential binding motif is located between amino acids 
E114 and D156 (Fig. 4-4).  Four different types of protein binding domains showed some 
similarities with this region in nsp 1 (Table 4-1).  In MHV, using deletion and truncation mutants 
it has been reported that nsp 1 interacts with viral proteins nsp 7 and nsp 10 between amino 
acids E84 and R166 (T84 and Q166 in BCoV), which fits within the BCoV putative motif (19) 
(Fig. 4-4).  This region of nsp 1 is therefore a potential conserved binding motif among group 2a 
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Figure 4-4.  BCoV nsp 1 Putative Interaction Motifs.  Results from SMART.  Putative 
binding motif I shows similarities with nucleic acid and protein binding zinc fingers.  The MHV 
nsp 1 sequence contains some conserved residues in this region.  The sequence in MHV found 
to have similarity to a zinc finger is noted with a dotted underline.  Putative binding motif II has 
conserved residues with MHV and resides within the experimentally defined protein binding 
region for MHV nsp 1(aa E84-R166). Putative binding motif III is similar to a binding domain 
known to interact with a cell cycle regulatory protein.  This motif contains the most conserved 
region between group 2 nsp 1 sequences, LRKxGxKG.  The predicted transmembrane (TM) 
domain in BCoV was only weakly predicted for MHV and therefore may only occur in BCoV or 
BCoV-like nsp 1 sequences.  Residues that were matches to the majority of the predicted motifs 
for each region (Table 4-1) are in bold. 
 1       36 56    76              
BCOV MSKINKYGLELHWAPEFPWMFEDAEEKLDNPSSSEVDIVCSTTAQKLETGGICPENHVMVDCRRLLKQECCVQSSLIREIVMNTRPYDL 
MHV MAKMGKYGLGFKWAPEFPWMLPNASEKLGNPERSEEDGFCPSAAQEPKVKGKTLVNHVRVNCSRLPALECCVQSAIIRDIFVDEDPQKV 
 
 
 90    110     135    155                            
BCOV EVLLQDALQSREAVLVTPPLGMSLEACYVRGCNPNGWTMGLFRRRSVCNTGRCAVNKHVAYQLYMIDPAGVCFGAGQFVGWVIPLAFMP 
MHV EASTMMALQFGSAVLVKPSKRLSIQAWTNLGVLPKTAAMGLFKRVCLCNTRECSCDAHVAFHLFTVQPDGVCLGNGRFIGWFVPVTAIP 
 
 
 179     191     210     225                 246 
BCOV VQSRKFIVPWVMYLRKCGEKGAYNKDHKR-GGFEHVYNFKVEDAYDLVHDEPKGKFSKKAYALIRGYRG 
MHV EYAKQWLQPWSILLRKGGNKGSVTSGHFRRAVTMPVYDFNVEDACEEVHLNPKGKYSCKAYALLKGYRG
Put. Binding Motif I
Put. Binding Motif II
Put. Binding Motif III
Predicted TM Domain
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coronaviruses and is likely a protein interaction region.  A similar binding motif was not predicted 
to exist in SARS-CoV (data not shown).  
 In BCoV a transmembrane domain was confidently predicted at positions P157-V179 by 
SMART and the transmembrane prediction program TMpred (Fig. 4-4).  In comparison, in MHV, 
a transmembrane domain is only predicted in the same region, amino acids 163-181, using 
TMpred.  Although significant, the overall score is much lower than in BCoV so it is unclear if 
this is a true transmembrane domain (Appendix III).  In SARS-CoV, no transmembrane domain 
was predicted (data not shown).  Hypothesizing that nsp 1 is an integral part of the replication 
complex, a transmembrane domain could aid in localizing replication complexes to membranes.   
 A third binding motif is predicted to exist at the C-terminus of BCoV nsp 1.  This C-
terminal predicted protein binding region exists downstream of the transmembrane domain (Fig. 
4-4).  Only a single known motif was found to have some similarities with the nsp 1 sequence in 
this region, band 4.1 homologues’ binding motif (Table 4-1).  This motif has been found on the 
intracellular region of transmembrane glycoproteins such as glycophorin C.  Protein 4.1 binds 
the motif in glycophorin C and is involved in red blood cell shape and stability (40).  More 
recently, protein 4.1 has been found to be more ubiquitously expressed and a component of 
centromeres and mitotic spindles in nucleated cells.  Depletion of the protein resulted in cell 
cycle arrest by causing G1 accumulation and preventing progression into the S phase (86).  
Interestingly, in MHV, nsp 1 has been shown to arrest the cell cycle in the Go/G1 phase (30).  In 
addition, a similar affect has been reported with SARS-CoV nsp 1 (164).  The predicted domain 
is within the highly conserved region containing LRKxGxKG (Fig. 4-4, boxed amino acids), 
making it plausible that all three viral nsp 1 proteins have this binding motif and are able to bind 
protein 4.1, or a related 4.1/FERM superfamily protein, resulting in cell cycle dysregulation. 
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Discussion  
 Analysis of nsp 1 sequences revealed both RNA secondary structure and amino acid 
sequence similarities.  In terms of protein sequence similarity, group 2a coronaviruses are 
highly conserved with greater than 60% similarity at the amino acid level.  While experimental 
data has shown that nsp 1 binds both viral RNA and proteins, the specific domains responsible 
for these interactions remain elusive.   The predicted putative interaction motifs are not 
significant enough to conclusively define, however the data are consistent with the experimental 
observations.  Putative RNA and protein binding motifs and possibly a transmembrane domain 
are therefore also likely conserved features of group 2a nsp 1 proteins.  Based on amino acid 
sequence alignments of the ORF 1b polyprotein, SARS-CoV was placed into group 2 as a 
distant relative of MHV and BCoV (141).  Considering the nsp 1 predicted RNA secondary 
structure and amino acid sequence, it appears that the distantly related SARS-CoV is both 
group 1-like and group 2-like.    Similarity between SARS-CoV and group 1a is equal to that 
observed for group 2a, and therefore may have functions that are both group 1 and group 2 like 
and could represent a link between the two groups.   
 The most conserved region in BCoV, MHV, and SARS-CoV, the sequence LRKxGxKG, 
is within a potential binding region that could bind a member of the protein 4.1/FERM 
superfamily, such as protein 4.1, a protein recently found to be necessary for cell division (86). 
The C-terminal portion of the protein has been implicated as the effector of mRNA decay and 
translation shutoff.  In MHV and SARS-CoV, deletion or mutation of the C-terminal portion of 
nsp 1 resulted in virus attenuation and a decrease in the observed cellular effects (115, 164, 
177).   In our truncation experiments, overexpression of only the C-terminal portion of p28 
resulted in more severely diminished accumulation of DI RNA compared to expression of only 
the N-terminal portion of p28 (Chapter II).  Thus, this may be a conserved function localized to 
the C-terminal portion of p28, and possibly due to interactions involving binding domains in that 
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region.  Interestingly, group 1 coronavirus HCoV229-E  nsp 1 has been reported to affect 
cellular mRNA levels when expressed from a plasmid (177).  This observation was not 
extensively studied and it is unclear if the C-terminal region of the protein is responsible as 
shown for SARS-CoV and MHV, but brings up the possibility of a conserved function among 
group 1 and group 2 nsp 1 proteins. 
 Although nsp 1 protein sequences among the coronaviruses are dissimilar in many 
respects, they may have similar functions.  It will be interesting to explore the functional 
similarities among different nsp 1 sequences and how these features differentially affect virus 
replication and pathogenesis.  As SARS-CoV nsp 1 appears to contain features of both group 1 
and group 2 coronaviruses, it may provide a common link between these divergent proteins and 
perhaps help identify functional relationships. 
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Chapter V.  Future Directions 
 
Introduction 
 The worldwide outbreak of SARS in 2003 resulted in an expanded interest in 
coronaviruses.  The sudden appearance, rapid spread, and high mortality caused by SARS-
CoV highlights the need for more efficient and more effective diagnosis, treatment, and 
prevention of viral diseases.  In order to achieve this, a better understanding of virus replication 
is required.   
 In this dissertation, fundamental research addressing the requirements for bovine 
coronavirus replication has been presented.  A second cis-acting higher order structure within 
the coding region of the nonstructural protein p28 was identified and shown to be required for 
replication of a DI RNA and proposed to also be required for genome replication.  In addition, 
although the replication requirement for p28 is not understood, it was shown to be an RNA 
binding protein that may function through interactions with cis-acting elements in the 5’ and 3’ 
untranslated regions.  Also, a novel 5’ and 3’ UTR dependent repression of cap-dependent 
enhancement of translation has been identified.  This apparent regulatory mechanism may have 
important ramifications for the regulation of viral translation and replication.  An analysis of the 
contributions of both the 5’ and 3’ UTRs in translation without the influence of viral proteins may 
provide a basis for re-evaluating the basic tenets of translation and regulation. 
  The identification of replication requirements may provide a basis for the development of 
specific virus-targeted therapeutics.  This research opens up future directions in the study of 
virus replication that will lead to a more complete understanding of how to better diagnose, treat, 
prevent, and perhaps cure illnesses caused by coronavirus infections.  
Identification of Cellular Proteins That Bind the SLV And SLVI cis-Acting Region 
 Cellular proteins of approximately 60 and 100 kDa were found to bind cis-acting 
replication stem-loops V and VI (Chapter II).  Since no viral proteins have been found to bind 
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specifically to this region, the unidentified cellular proteins may have a role in the cis-acting 
function of SLV and VI.  Identification of these proteins would further expand our understanding 
of coronavirus replication and how SLV and VI function in replication. 
Experimentally Define the RNA Binding Domain of p28 
 The first nonstructural protein, p28, was shown for the first time to be an RNA binding 
protein.  Although bioinformatics has established a putative RNA binding domain in p28, this 
needs to be experimentally tested.  If our hypothesis is correct, the N-terminal portion of p28, 
which is found in all known coronavirus DI RNAs and required for virus replication, contains the 
RNA binding domain.  Therefore, gel shift experiments with only the N-terminal portion of p28 
would still be expected to bind the cis-acting stem-loop structures identified in Chapter II.  
Experimental elucidation of this domain would help define the replication requirement for the N-
terminal portion of p28 separate from the secondary structure cis-requirement of SLV and VI.  
The dual replication requirement of the N-terminal portion of p28 secondary structure and 
protein presents a unique targeting opportunity that should be further explored. 
Expand Translation Studies  
 Translation studies in vitro using RRL and a Renilla Luciferase reporter construct fused 
to the BCoV 5’ and 3’ UTRs showed a repression of cap-dependent translation.  It is 
hypothesized this repression is mediated by a 5’-3’ UTR interaction via cellular proteins 
(Chapter III).  This may represent a transcriptionally poised but inactive complex.  To begin to 
investigate the primary hypothesis that viral proteins are involved in translation through 
interactions with the cis-acting elements within the UTRs, three approaches might be taken.  
First, in vitro translation using BCoV infected and prepared lysates.  This approach will not 
elucidate specific factors that influence translation but will show how translation proceeds with 
viral proteins in a limited system and in the absence of competition with cellular mRNAs.  
Second, translation of reporter constructs in both uninfected and BCoV infected cells.  This 
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approach will take the previous step further and look at translation with the influence of virus 
infection in cells. It is expected that in a competitive and more complex environment the factors 
that influence translation will be varied.  These studies will provide information on how the 
genomic RNA is initially translated in the presence of cellular mRNAs and cellular factors. 
Thirdly, using in vitro translation, individually expressed and purified viral proteins can be added 
to translation reactions to test how these regulate translation.  Although this approach will not 
determine a mechanism of action, the effects of individual viral proteins on translation can be 
studied.  More extensive experiments including both RNA and protein binding domain mutants 
and how they affect translation will be necessary to show a direct interaction results in 
translation modulation. 
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The Negative-Strand Counterparts of SLV and VI Bind Cellular Proteins and p28 
 Although it is not known if the negative strand counterparts to SLV and SL VI are 
required for replication, it is possible they are involved in RNA synthesis of the complementary 
strand.  No viral proteins have been shown to bind negative strand cis-elements, but cellular 
proteins including PTB and hnRNP A1 have been shown to bind both positive and negative 
strand UTRs in MHV (70, 71, 96, 97).  Although their exact function is not understood, they are 
thought to be involved in RNA synthesis of the complementary strand.  Thus, cellular proteins 
that bind to the negative strand counterparts of these cis-acting replication elements could 
potentially be involved in RNA transcription.  To determine if viral or cellular proteins bind to the 
negative strand regions of cis-acting SLV and SLVI gel shift assays were performed using BCoV 
infected and uninfected cellular lysates as described previously in Chapter II.  The predicted 
secondary structure of the negative strand is shown in Figure A1-1A.  To synthesize the 
negative strand of this region the previously described pSLV-VI was digested using the EcoR1 
restriction site and transcribed using the SP6 promoter.  Binding interactions were tested using 
gel shift assays.   
The Negative-Strand Counterparts of SLV and VI Bind Cellular Proteins 
 Gel shift identified one cellular complex that binds the complementary SLV and SLVI 
probe (Fig. A1-1B).  The probe is completely bound when the infected lysate was used but there 
are no obvious indications that viral proteins are bound.  This could be due to differences in the 
lysate quantitations or additional protein-protein interactions that do not bind directly to the RNA.  
In order to determine the number and approximate molecular weight(s) of the protein(s) in the 
complex, UV crosslinking was performed.  UV crosslinking using the uninfected cell lysate 
revealed multiple proteins binding to the negative strand of SLV-VI (Fig. A1-1C).  The same two 
cellular proteins of ~60kDa and 100kDa that bind the positive strand stem-loops also appear to 
bind the negative strand stem-loops.  At least one other major protein of approximately 70kDa 
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Figure A1-1.  SLV-VI Negative-Strand.  A.  Mfold predicted secondary structure of SLV-VI(-).  
B. Gel shift assay indicates one cellular complex binds SLV-VI(-).  C.  UV crosslinking identifies 
five cellular proteins binding to SLV-VI(-).  The ~60kDa and ~100kDa proteins also bind to the 
positive strand. 
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and several minor proteins (35-55kDa) also bind the negative strand.  The identities of these 
proteins are currently unknown. 
The Negative-Strand Counterparts of SLV and VI Bind p28 
 It is not known if the cis-acting requirement of stem-loop V and VI is in the positive or 
negative strand, and the negative strand region may have a role in virus replication such as 
RNA synthesis of the complementary strand.   
 The results show that p28 does bind the negative strand counterparts of these two stem-
loops (Fig. A1-2A,left).  The shifted band is decreased when a cold competitor RNA of the same 
sequence was added to the reaction, suggesting the interaction has both specificity and affinity 
for the SLV-VI (-) region.  Although the significance of the negative strand stem-loops in this 
region is not known, there is support for the two stem-loops functioning together in the negative 
strand as well, as p28 does not bind the SL VI(-) or SLV(-) probes alone (Fig. A1-2A, right).  In 
addition, the viral 2’-O-methyltransferase, nucleocapsid, and exonuclease do not bind the 
negative strand of this region (Fig. A1-2B). 
 Although the replication requirements for the negative strand counterparts of stem-loops 
V and VI are unknown, the results demonstrate this region binds both viral and cellular proteins, 
suggesting they may function in virus replication.  As was shown for the positive strand, these 
predicted stem-loop structures in the negative strand may function as one element.  In order to 
better understand the significance of these negative strand elements, more research is needed 
to determine the significance of p28 binding to this region as well as the identities of the cellular 
proteins. 
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Figure A1-2.  p28 Binds the Negative-Strand of SLV-VI.  A. p28 specifically binds SLV-VI(-) 
(left), but not either stem-loop individually (right).  B. The viral 2’-O-methyltransferase (MT), 
exonuclease (Exo), and nucleocapsid (N) proteins do not bind SLV-VI(-). 
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An ~60kDa Cellular Protein Binds SLVI 
 Three cellular complexes were found to bind SLV-VI by gel shift analysis as discussed in 
Chapter II.  UV-crosslinking further resolved these complexes into two proteins of approximately 
60kDa and 100kDa.  To investigate protein complexes that bind each stem-loop independently, 
each was tested separately with BCoV infected and uninfected cellular lysates.  In gel shift 
assays where probes representing stem-loop V (nts 231-316) and stem-loop VI (nts 309-343) 
individually were used, one cellular complex was found to bind each probe (Fig. A1-3A).  UV 
crosslinking was used to determine how many factors comprised each complex and their 
approximate molecular weight.  The results indicate that the ~60kDa protein found to bind the 
SLV-VI probe binds SLVI independently.  The higher molecular weight protein that binds SL V 
and VI together, does not bind SLVI alone (Fig. A1-3B).  It is not known if one of these proteins 
binds SLV only.   
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Figure A1-3.  An ~60kDa Cellular Protein Binds SLVI.  A.  Gel shift assays show a single 
cellular complex binds SLV and SLVI individual probes.  B.  UV-crosslinking indicates SLVI 
binds only the ~60kDa protein. 
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p28 Nonspecifically Binds SLV-VI 
 As we were unable to detect viral proteins binding to the SLV-SLVI region with virus 
infected cellular lysates, we tested binding of E.coli expressed and purified recombinant viral 
proteins (Chapter II).  The cis requirement for the p28 nucleotide sequence and separate 
requirement for the translation product made it tempting to speculate that p28 may bind the cis-
acting stem-loops within its own coding region and function as a regulatory protein.  Gel shift 
analysis was used to identify interactions between p28 and its own coding region. No binding of 
p28 to SLV-VI was found (Chapter II).  To determine if p28 could interact with these stem-loops 
in a nonspecific manner, the experiments were repeated in the absence of competitor yeast 
tRNA (y.tRNA).  The results indicate that even in the absence of the competitor RNA, p28 does 
not bind to stem-loop V or stem-loop VI (Fig. A1-4A).  Interestingly, when the probe containing 
both stem-loop V and VI was tested in the absence of tRNA, some nonspecific, binding was 
observed (Fig. A1-4B), suggesting these two stem-loops which are close together may at least 
partially function together and form a protein binding site that can interact with p28.  This 
nonspecific association may be the result of electrostatic interactions between positive residues 
in p28 and SLV-VI.  
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Figure A1-4.  Nonspecific Binding of p28 to SLV-SLVI.  A.  Even in the absence of a 
nonspecific competitor, p28 does not bind to SLV or SLVI independently.  B.  Gel shift assay 
shows nonspecific binding of p28 to SLV-VI only in the absence of y.tRNA.  The y.tRNA binds 
the RNA probe as the free probe is slightly shifted with increasing amounts of y.tRNA. 
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SLV-SLVI Mutant Binding Interactions 
 It is known that disruption of cis-acting stem-loop VI is detrimental to DI RNA replication 
(20).  Mutation of the DI RNA to disrupt the base pairing of the stem of stem-loop VI at 
nucleotides 315 and 318 resulted in a loss of replication.  Compensatory mutations that restored 
base pairing also restored replication, suggesting the structure of stem-loop VI is important for 
DI RNA replication (20).  Therefore, a probe with the same mutations was used to determine if 
potential trans-acting interactions were modified. An inability of a protein to bind to the required 
stem-loop may explain the defect in replication. Gel shift assays were used to detect any 
differences in binding interactions between wildtype and mutant probes.  The previously 
described SLV-VI probe (wildtype) was mutated to include base substitutions at nucleotide 
positions 315 and 318 in the stem of stem-loop VI (pSLV-SLVImut).  The secondary structure of 
the mutant as predicted by mfold is shown in Figure A1-5A. 
SLV-VI Mutant Binds Cellular Proteins 
 Incubation of the probe with the stem-loop VI mutant with cellular and virus infected 
lysates revealed only two cellular complexes compared to the three complexes in the wildtype 
(Fig. A1-5B; lanes 2 & 3 compared to lanes 5 & 6).  UV crosslinking was used to determine how 
many factors comprised each complex and their approximate molecular weight.  The results 
indicate that two cellular proteins (MW 60 & 100kDa) bind to the stem-loop V and VI region, 
including the stem-loop VI mutant (Fig. A1-5B).  Although there is a difference in the number of 
complexes identified by gel shift analysis, it does not appear as though a unique protein-RNA 
interaction was disrupted with the mutant probe.  It is possible that the three cellular complexes 
represent different molecular ratios of RNA to proteins and one of these was disrupted by the 
mutant.  Alternatively, additional protein-protein interactions could exist between proteins that do 
not directly bind RNA that would alter the mobility of the complex but would not be identified by 
this assay. 
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Figure A1-5.  SLV-VI Mutant Binds Cellular Complexes.  A. Mfold secondary structure 
predictions of wildtype and SLVI mutant stem-loops.  B.  Gel shift analysis reveals only two 
shifted cellular complexes in the SLV-VI mutant. 
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SLV-SLVI Mutant Binds p28 
 The results presented in Chapter II indicate that p28 does not bind to its own coding 
region with great affinity or specificity.  Interestingly, when the probe containing both stem-loop 
V and VI was tested, some nonspecific, low affinity binding was observed (Fig. A1-4B,).  To 
further examine the interaction between the two stem-loop structures and p28, pSLV-VImut. 
was used in gel shift assays.  Incubation of the mutant probe with p28 showed similar results to 
what was observed with the wildtype probe.   p28 binds the mutant probe weakly and 
nonspecifically (Fig. A1-6).  Competition with increasing amounts of yeast tRNA outcompetes 
p28 binding.  Collectively, it appears as though p28 may bind to the loop of SLVI and an 
unknown region of SLV, as the same binding pattern was observed with both wildtype and the 
mutated probe.  
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Figure A1-6.  p28 Nonspecifically Binds SLV-VI Mutant.  Although the mutations made to 
SLVI interfere with DI RNA replication, they do no interfere with nonspecific interactions with 
p28. 
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Electrophoretic Mobility Shift Assay (EMSA)/Gel Shift Assay   
 α32P-UTP RNA probes were synthesized using linearized plasmid DNA and T7 RNA 
polymerase (Promega). Approximately 2.5μg of DNA was added to an in vitro transcription 
reaction following the manufacturer’s protocol in a final volume of 50μl.  Acetylated BSA 
(0.1μg/μl) was also included in the reactions.  Transcription reactions were incubated at 37°C 
for one hour.  RQ RNase free DNase was added (1U/μg DNA) and incubated an additional 30 
minutes.  50μl of sequencing stop dye (80% Formamide, 1mM EDTA pH 8.0, 0.1% 
bromophenol blue, 0.1% xylene cyanol) was added and reactions were loaded onto 5-9% 
polyacrylamide/7%urea gel.  Gels were exposed to Kodak XAR-5 film for 10minutes.  Bands 
were excised from gel and eluted overnight with rotation at 4°C in elution buffer (0.5M 
ammonium acetate, 1mM EDTA).  RNA was then ethanol precipitated and resuspended in 
water.  Cerenkov counts were determined by scintillation counting. 
 Gel shift assays were performed following the protocol in Silvera, et. al (140), with minor 
modifications.  Recombinant E.coli expressed proteins, BCoV infected, or mock-infected cell 
lysates were incubated in binding buffer (5mM HEPES pH 7.9, 40mM KCl, 2mM MgCl2, 2mM 
DTT, 4% glycerol, 0.25% heparin, 20U RNasin (Promega), 1x EDTA-Free Complete protease 
inhibitors (Roche), 0.5ug/ul yeast tRNA) for 10 min. at 30°C.  Approximately 4x104cpm of each 
RNA probe was then added to the reaction and incubated an additional 10min.  Following 
incubation, 2ul of 50% glycerol was added for gel loading and reactions were loaded onto a 5% 
nondenaturing polyacrylamide gel (prerun 100V, 20min) and run for approximately 4 hours. A 
Bio-Rad 16x16cm vertical electrophoresis system connected to a refrigerated circulating water 
bath (4°C) was used. Gels were dried using a Bio-Rad air dryer. Dried gels were exposed to 
Kodak XAR-5 film and results visualized by autoradiography. 
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Appendix II:  Translation 
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cis-Acting Replication Elements Within the Nsp 1 Coding Region Do Not Affect 
Translation.   
 BCoV DI RNA replication has been shown to require the 5’-terminal portion of the coding 
region of the first nonstructural protein (nsp1) which includes two cis-acting stem-loop 
structures, SLV and SLVI.  The exact roles these structures play in virus replication are 
unknown.  Because the luciferase reporter constructs only include the UTR, it was possible an 
important translation regulatory element was missing.  To determine if these stem-loops or nsp 
1 sequence have a role in regulating translation, a construct with the required coding region 
sequence was included.  This construct, BCoV(1-396)-288 includes the entire 210nt 5’ UTR and 
186 nucleotides of nsp 1 sequence. The results show that the translation levels of BCoV(1-
396)-288 are the same as UTR210-288, indicating this cis-acting region did not impact 
translation (Fig. A2-1A).  To eliminate the possibility that luciferase activity was altered due to 
the extra N-terminal amino acids, these results were confirmed with translation experiments 
using 35S-Met in vitro translation.  The resulting translation product is larger in size, but 
translation is equal to UTR210-288 based on phosphorimager quantitation (Fig. A2-1B).  These 
results are consistent with those presented in Figure 2-2C in which there was no change in 
translation of SLV mutant DI RNAs compared to wildtype. 
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Figure A2-1.  BCoV(1-396)-288 in vitro Translation.  The partial p28 coding region present in 
the BCoV DI RNA does not appear to influence translation of an RLuc reporter construct.  A.  
Translation levels of BCoV(1-396)-288, which includes cis-acting SLV-VI, are the same as 
UTR210-288.  B.  35S-Met. translation of BCoV(1-396)-288 and UTR210-288. 
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uORF Mutants 
 As shown in Chapter III, Figure 3-4B, when the uAUG was mutated (m.uAUG-288), 
there is no change in translation and levels remain equal to that of the wildtype UTR210-288.  
This result was surprising since this uAUG is a highly conserved element and is found in all 
coronaviruses sequenced to date with only one exception (Brian, D.A., Gustin, K.M., 
unpublished data).  To more fully understand the function or lack thereof of the uAUG, more 
mutants were made to test for reinitiation and usage of the uAUG. 
 Reinitiation of ribosomes after translation termination is believed to occur when there is 
sufficient distance between the uORF stop codon and the next start codon (31, 83).  There must 
be appropriate timing for initiation factors to reassemble and reinitiate translation.  A minimum of 
50 nucleotides are needed for reinitiation to occur and approximately 80 are necessary for 
efficient reinitiation  (31, 83).  In BCoV, there would be sufficient distance for reinitiation, with 
over 80 nucleotides between the uORF stop codon (nt124) and the main ORF AUG at position 
211.  Two mutants were designed to test for reinitiation, m.124STOP-288 and m.124/184STOP-
288 (Fig. A2-2).  The uAUG is in-frame with the main ORF and contains three in-frame stop 
codons.  Using the native sequence to our advantage, we were able to design mutants in which 
each stop codon was mutated to an amino acid codon, extending the uORF down to the next in-
frame stop codon.  Using this method we were able to extent the length of the uORF and 
decrease the distance to the 211 AUG, thus decreasing the chances for reinitiation.   For 
m.124STOP-288 the normal uORF stop codon (nt124) TAG was changed to TCG, increasing 
the length of the uORF to twenty-eight amino acids, and thus decreasing the distance from the 
stop codon (nt184) to the main ORF AUG at 211 to twenty-four nucleotides.  Similarly, in 
m.124/184 STOP-288 both the 124 and 184 stop codons were mutated (Fig. A2-2).  Translation 
of this uORF would make a peptide of thirty-four amino acids and decrease the distance from 
the final stop codon at nucleotide 202 to the 211 AUG to only six nucleotides. 
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Figure A2-2.  uORF Mutant Design.  A.  To test for uAUG usage and reinitiation, constructs 
were made by mutating in-frame stop codons, extending the length of the uORF and decreasing 
the distance between the termination codon and the 211AUG reinitiation site.  B.  Construct 
diagrams. 
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If the uAUG is used, translation of the main ORF should decrease because reinitiation should 
not be able to occur with only twenty-four and six nucleotides between the uORF stop and AUG 
(Fig. A2-2A).  Consistent with the previous observation that mutation of the uAUG does not 
affect translation, m.124STOP-288 translation levels are wildtype like indicating the uAUG is not 
being used and leaky scanning past the uAUG is most likely occurring.  However, 
m.124/184STOP-288 translation levels are significantly decreased at the 60 and 90 minute 
timepoints (Fig. A2-3A).  In this case it is possible usage of the uAUG did attenuate translation, 
but it is also possible the mutations resulted in unintended changes that affected usage of the 
main AUG.  
 Figure A2-3B shows translation of these RNAs using 35S-Met and SDS-PAGE.  Based 
on phosphorimager quantitation, the major translation product in lanes 1, 2, 4, 5 are similar.    
Translation of uORF fusion-288 resulted in one light upper band which is representative of 
initiation from the uAUG and a darker band which represents translation from an AUG within the 
RLuc coding region.  m.124STOP-288 and m.124/184STOP-288 only have a single band, 
indicating translation from only the 211 AUG.  From this experiment m.124/184STOP translation 
levels do not appear decreased as in the luciferase assay, indicating that perhaps the previously 
observed decrease in translation is not as significant.  In addition, there are no lower bands in 
either m.124STOP-288 or m.124/184STOP-288 that would indicate reinitiation may have 
occurred at an AUG downstream within the coding region as with uORF fusion-288. Thus leaky 
scanning past the uAUG appears to occur most of the time. 
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Figure A2-3.  uORF Mutants.  Results from in vitro translation of uAUG/uORF RLuc constructs.  
A.  Translation levels of uORF mutant m.124STOP-288 are similar to translation levels of 
UTR210-288 and m.uAUG-288.  m.124/184STOP-288 translation levels are decreased 
compared to m.124STOP-288, UTR210-288, and m.uAUG-288.  B.  35S-Met. translation of 
uORF mutant constructs (90min.).  Translation of m.124STOP-288 and m.124/184STOP-288 
appear similar and initiation is from only the 211AUG. 
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The 5’ UTR uAUG Attenuates Translation in the Absence of the Viral 288nt 3’ UTR. 
 Translation of  capped transcripts addressing the influence of a potential regulatory 
uAUG in the 5’ UTR, (m.uAUG-288), did not show any apparent regulatory role and translation 
initiation from the uAUG occurred less than 25% of the time (uORF fusion-288) (Fig. 3-4C and 
3-4D). However, translation of capped transcripts of  m.uAUG-40Δp(A) resulted in significantly 
increased translation over UTR210-40Δp(A) at multiple timepoints (Fig. A2-4A).  This result 
suggested that the uAUG in UTR210-40Δp(A) was attenuating translation of the main ORF and 
that by removing the uAUG (m.uAUG-40Δp(A)), translation was increased.   Contradictory to the 
results shown in Figure 3-4, here the uAUG does appear to function in translation regulation of 
the main ORF, but only in the absence of the viral 3’ UTR.  In Chapter III, cap-dependent 
translation was shown to be repressed via a 5’-3’ UTR mediated interaction. Therefore, we can 
hypothesize that in the absence of the viral 3’ UTR, and thus the 5’-3’ UTR interaction, the 
uAUG is used more and therefore regulates translation of the downstream ORF.   
 To more thoroughly examine the observation that the uAUG was regulating translation in 
the context of the non-viral 3’ UTR, an additional construct was made.  uORF fusion-40Δp(A) 
was used to determine if usage of the uAUG was altered in the absence of the viral 3’ UTR (Fig. 
A2-4B).  For comparison, uORF fusion-288, which was shown to initiate translation from the 
uAUG ~20% of the time (Fig. 3-4), was used.  Although this construct has a poly(A) tail, it has 
already been shown that the proposed 5’-3’ UTR interaction is within the 5’ UTR leader 
sequence and 3’ UTR bulged stem-loop and adjacent pseudoknot region and is independent of 
the poly(A) tail.  It is expected that translation levels of uORF fusion-288 without a poly(A) tail 
would be significantly lower.  Translation levels of uORF fusion-40Δp(A) were significantly 
increased compared to uORF-fusion-288 (p=0.01, 90min timept) (Fig. A2-4C).  Although the 
increase was only 20% by the 90 minute timepoint, a definite change in translation is apparent 
at multiple timepoints, suggesting that in the absence of the viral 3’ UTR, the uAUG is used 
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Figure A2-4.  The 5’ UTR uAUG Attenuates Translation in the Absence of the Viral 288nt 
3’ UTR.  A.  Translation levels of m.uAUG-40Δp(A) are increased compared to UTR210-40Δp(A).  
B.  Construct diagrams of uORF fusion-40Δp(A) and uORF fusion-288.  C.  Left:  Translation 
levels of uORF fusion-40Δp(A) compared to uORF fusion-288 (20% difference at 90min.).  
Right: 35S-Met translation.  Based on phosphorimager quantitation, translation from the uAUG in 
uORF-40Δp(A) is 30% higher than uORF fusion-288 (upper band).  However, the ratio of 
translation products (upper band: lower band) indicate the uAUG is used ~23% of the time in 
both uORF fusion-288 and uORF-40Δp(A).   
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more and therefore decreases translation of the main ORF.  This data supports the hypothesis 
that in the absence of the viral 3’ UTR, the uAUG is used more and therefore regulates 
translation of the downstream ORF. 
 As a secondary method of analysis, 35S-Met translation of uORF fusion-40Δp(A) was 
done to determine if the uAUG was being used more.  Figure A2-4C shows 35S-Met translation 
products at 90 minutes.  There are two bands, a minor band representing translation from the 
uAUG and a major translation product that results from leaky scanning and initiation at a 
downstream coding region AUG.  Quantitation of the upper bands, representing translation from 
the uAUG indicates that translation of uORF fusion-40Δp(A) is increased 30% compared to 
uORF fusion-288 (Fig. A2-4C).  This indicates the uAUG in the context of the 40nt 3’ UTR is 
being used 30% more than in the context of the viral 3’ UTR.  Therefore, in support of the 
hypothesis that the usage of the uAUG is affected, and that the uAUG is used more in the 
absence of the viral 3’ UTR, ribosomes initiate translation at the uAUG in UTR210-40Δp(A) ~30% 
more than in UTR210-288.   
 A comparison of the ratios of translation products from the uAUG and the downstream 
coding region AUG from uORF fusion-40Δp(A) and uORF fusion-288  indicate translation from 
the uAUG occurs ~23% of the time and leaky scanning accounts for over 70% of total 
translation in both cases (Fig. A2-4C).  These results therefore suggest that the uAUG is not 
necessarily being used more in constructs with the 40nt 3’ UTR, but perhaps that in the absence 
of the 3’ UTR and thus the repressive 5’-3’ UTR interaction, there are more initiation events 
overall.  Subsequently, there are more ribosomes that initiate translation at the uAUG, resulting 
in an attenuation of translation of the main ORF.  These results support a model for a 5’-3’ UTR 
interaction and further suggest that the 5’-3’ UTR interaction may repress cap-dependent 
translation through inefficient recruitment or binding of cap-binding initiation factors or ribosome 
subunits. 
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Figure A2-5. Renilla Luciferase Construct Diagrams.  Construct names are given as 5’ UTR 
sequence – 3’ UTR sequence. 
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Figure A2-5 (continued).  Renilla Luciferase Construct Diagrams. 
AAAAAA5’ Renilla Luciferase
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Figure A2-5 (continued).  Renilla Luciferase Construct Diagrams.
AAAAAA5’ Renilla Luciferase
BSL
PK
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C
D
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SL
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Table A2-1.  Renilla Luciferase Assay Results From in vitro Translation.  
construct
capped
Time AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV
0 0.03 0.01 0.04 0.03 0.03 0.01 0.02 0.00 0.04 0.04 0.05 0.04 0.04 0.06
10 278.83 34.72 109.51 46.38 237.47 154.10 704.10 266.26 259.03 121.66 176.85 26.73 137.45 76.98
20 712.40 23.29 233.90 81.87 419.73 239.73 1423.33 526.28 648.13 243.66 544.03 190.94 381.82 140.01
40 915.90 174.49 310.57 83.32 458.50 201.74 2018.33 503.80 975.83 175.67 802.93 61.30 485.28 149.15
60 1093.47 161.07 351.00 78.23 551.67 254.67 2364.33 701.76 999.90 286.49 953.98 154.74 682.30 257.66
90 1272.00 103.01 427.33 28.35 515.83 163.94 2366.67 260.63 1351.33 86.03 988.73 120.94 711.72 192.95
uncapped
0 0.04 0.02 0.03 0.01 0.04 0.04 0.02 0.00 0.06 0.02 0.14 0.05 0.06 0.03
10 235.27 99.76 110.03 41.20 121.26 81.48 359.45 116.18 158.27 80.65 154.57 51.88 180.95 60.89
20 561.83 235.16 258.40 66.97 262.53 118.29 731.60 169.31 401.53 54.28 460.93 72.40 475.58 63.45
40 848.93 162.82 331.10 140.76 389.65 93.51 937.73 334.87 523.07 72.28 620.70 112.63 515.45 55.95
60 1127.40 205.79 360.00 138.30 275.63 151.69 982.23 277.27 633.67 68.99 711.07 107.96 540.25 65.55
90 1263.67 127.42 428.60 122.09 414.90 78.16 1266.45 215.08 611.50 104.75 708.93 136.84 564.23 52.41
construct
capped
Time AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV
0 0.03 0.00 0.05 0.03 0.03 0.03 0.04 0.02 0.06 0.01 0.07 0.06 0.02 0.02
10 300.30 171.33 186.03 71.73 163.97 25.59 268.37 81.70 146.91 74.46 148.05 22.98 385.80 211.64
20 751.67 256.03 305.40 58.19 327.80 82.85 671.70 169.62 365.30 172.07 454.58 82.25 645.53 38.79
40 1180.00 196.85 483.37 60.01 500.47 79.17 1090.17 121.97 688.77 237.65 653.80 73.50 780.47 147.90
60 1476.00 231.51 585.60 131.37 435.27 146.21 1173.67 85.15 868.87 15.73 818.10 76.71 829.10 245.14
90 1668.00 144.76 745.17 96.03 586.17 144.75 1276.00 139.53 1007.70 178.43 977.05 41.33 1022.07 100.03
uncapped
0 0.04 0.02 0.03 0.00 0.05 0.06 0.06 0.01 0.03 0.03 0.06 0.05 0.03 0.03
10 153.33 21.85 80.41 34.15 182.85 141.96 151.60 41.30 146.97 16.70 57.35 18.57 86.75 57.62
20 384.17 40.22 157.42 54.91 295.00 172.18 352.25 57.91 393.53 49.20 178.30 60.82 194.09 89.25
40 576.83 61.02 247.23 86.77 388.33 233.66 544.50 34.37 502.33 85.01 269.47 113.08 262.50 107.15
60 817.37 47.08 281.67 93.79 434.47 202.07 610.40 104.93 582.37 100.36 310.27 140.07 309.37 115.33
90 1038.17 76.38 366.03 112.39 472.83 177.87 632.05 89.59 538.53 30.78 406.97 160.37 353.73 149.52
 BCoV UTR210 
5'OPT.
BCoV UTR210-Δp(A) BCoV UTR210 
Δ3'UTRΔp(A)
 Δ5'UTR Δp(A) Rluc 20 Δp(A)
BCoV UTR210-
40nt3' 
Rluc 20 40nt3' Rluc 20 40nt3'Δp(A)
BCoV UTR210-
40nt3' Δp(A) UTR210 FLIP-Δp(A)UTR210 FLIP
RL20 FLIP-Δp(A)RL20 FLIP
 126
 
Table A2-1 (continued).  Renilla Luciferase Assay Results From in vitro Translation. 
 
 
 
construct
capped
Time AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV
0 0.06 0.01 0.03 0.01 0.03 0.02 0.04 0.04 0.04 0.03 0.03 0.03 0.05 0.05
10 279.13 32.89 381.93 103.49 478.10 224.34 420.03 218.92 249.37 63.96 105.16 23.25 110.10 5.50
20 743.37 82.51 1030.93 119.26 1187.00 170.24 876.53 361.92 432.67 45.24 250.80 34.15 316.00 22.27
40 1049.70 101.01 1444.33 51.83 1542.33 247.77 1068.93 386.03 700.17 35.89 305.88 31.60 428.10 23.39
60 1117.50 187.72 1781.67 139.09 2010.00 79.70 1301.33 347.93 621.50 44.16 319.15 65.57 457.83 42.64
90 1296.00 95.00 2218.00 300.13 2217.67 185.38 1425.00 153.16 869.77 174.35 388.28 34.48 493.87 34.90
uncapped
0 0.03 0.01 0.02 0.00 0.04 0.01 0.04 0.01 0.04 0.02 0.04 0.03
10 120.23 14.31 534.27 368.32 156.81 80.19 242.48 124.66 107.06 41.78 101.81 35.93
20 419.90 57.51 1016.03 511.87 379.58 121.57 649.33 274.59 281.80 93.60 249.77 124.01
40 885.97 167.15 1300.00 617.60 534.43 129.32 924.48 341.25 345.54 205.97 283.90 152.75
60 1061.00 71.44 1206.33 271.77 607.40 96.55 870.75 143.58 459.80 94.81 319.43 193.72
90 1337.33 54.17 1379.00 247.36 727.75 125.04 1050.48 167.82 586.33 156.87 369.03 136.14
construct
capped
Time AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV AVG STDEV
0 0.05 0.03 0.02 0.01 0.03 0.00 0.02 0.00 0.23 0.08 0.17 0.07
10 169.46 66.01 247.13 66.43 346.00 70.48 272.63 63.43 155.60 28.96 81.42 14.25
20 483.44 90.69 425.13 37.53 833.07 118.35 706.67 164.47 463.07 55.98 276.93 19.20
40 786.08 160.28 588.63 112.51 1376.33 394.05 843.07 107.25 661.83 138.94 425.93 42.02
60 799.96 337.54 574.50 54.99 1819.33 803.69 1114.87 193.35 743.93 58.21 466.30 53.42
90 1105.86 169.81 747.80 84.49 1644.00 156.29 1236.67 184.80 815.40 87.60 542.07 86.20
uncapped
0 0.04 0.01 0.02 0.00 0.03 0.01 0.03 0.01 0.16 0.08 0.09 0.01
10 200.00 24.45 76.24 25.25 347.50 57.69 84.57 14.74 93.29 15.76 99.41 22.14
20 483.73 140.55 160.10 45.44 472.61 376.69 210.80 36.03 341.87 71.15 323.17 27.42
40 839.70 44.26 183.40 25.03 751.80 149.82 319.90 27.38 481.50 23.19 469.67 17.50
60 1037.33 14.57 179.23 72.89 938.77 123.27 373.60 62.29 543.63 134.99 532.07 15.51
90 1200.73 187.11 222.40 48.51 1097.37 285.15 412.40 51.47 580.03 96.27 587.43 32.93
UTR210-Oct. UTR210-PKBCoV 1-396
m.uAUG  m.uAUG-40nt3' m.uAUG- 40nt3' 
Δp(A) m.124 stop
sg7 Rluc-40nt3' 
Δp(A) sg7 Rluc-40nt3' 
Not Tested
uORF fusion-
40Δp(A)uORF fusion
sg7 Rluc
m.124/184stop
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in vitro Translation Assay 
in vitro Translation 
 Translation of RLuc RNAs were performed using rabbit reticulocyte lysate (RRL) 
(Promega), following the manufacturer’s protocol.  100ng of RNA (quantitated by 
spectrophotometer and Ethidium Bromide formaldehyde gel electrophoresis) was added to 
reactions containing 40U of RNasin (Promega), 0.5μl each of 1mM amino acid mixtures (-)Met 
and (-)Cys  and water to a total volume of 15μl.  35μl of RRL was added to each reaction.  
Reactions were incubated at 30°C for 90 minutes and 2.5μl aliquots were taken at the indicated 
timepoints, frozen in a dry ice/ethanol bath, and stored at -80°C.  Independent translation 
reactions for each construct were performed a minimum of three times.   
Luciferase Assay  
 50μl of Renilla luciferase assay reagent (Promega) was added to each 2.5μl timepoint 
aliquot and counted three times using a TD20/20 luminometer  (luminometer settings: 2 second 
delay, 10 second integration).  Results are presented as the averages of at least three 
independent experiments. 
Radioactive in vitro translation 
 Translation reactions using 35S-Met were performed using RRL (Promega), following the 
manufacturer’s protocol.  500ng of RNA (quantitated by spectrophotometer and Ethidium 
Bromide formaldehyde gel electrophoresis) was added to reactions containing 40U of RNasin 
(Promega), 1.0μl of 1mM amino acid mixtures (-)Met,  2μl of 35S-Met (20μCi) and water to a total 
volume of 15μl.  35μl of RRL was added to each reaction.  Reactions were incubated at 30°C 
for 90 minutes and 5.0μl aliquots were taken after 90 minutes, frozen in a dry ice/ethanol bath, 
and stored at -80°C.  SDS loading dye was added to each 5μl aliquot, heated at 100°C for 2 
minutes and loaded onto a 12% Tris-glycine Ready gel (Biorad).  Following SDS-PAGE, gels 
were fixed in 30% methanol/10% glacial acetic acid/ 3%glycerol for 1 hour, impregnated with 
 128
Enhance Fluor (Perkin Elmer) for 1 hour, precipitated in water for 30 minutes and then dried 
using a slab gel dryer.  Results were visualized and quantitated using a phosphorimager. 
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Appendix III:  Bioinformatics 
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B. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A3-1.  Nucleotide Sequence Alignment of Group 1 and Group 2 nsp 1 5’ Terminal 
Region.  A.  Group 2 coronavirus sequence alignment.  B.  Group 1 coronavirus sequence 
alignment.  SARS-CoV sequence is shown in both alignments.  Approximate regions of 
secondary structures are indicated.  Regions corresponding to SLV have double overline.  
Approximate regions corresponding to SLVI have bold overline. 
                        1                                                                   70
    BCoV 211-350    (1) ATGTCGAAGATCAACAAATACGGTCTCGA-ACTACACTGGGCTC-CAGAATTTCCATGGATGTTTGAGGA
HECV4408 211-350    (1) ATGTCGAAGATCAACAAATACGGTCTCGA-ACTACACTGGGCTC-CAGAATTTCCATGGATGTTTGAGGA
HCoV-OC43 211-350    (1) ATGTCGAAGATCAACAAATACGGTCTCGA-ACTACACTGGGCTC-CAGAATTTCCATGGATGTTTGAGGA
    PHEV 211-450    (1) ATGTCGAAGATCAACAAATACGGTCTCGA-ACTATACTGGGCTC-CAGAATTTCCATGGATGTTTGAGGA
 MHV A59 211-350    (1) ATGGCAAAGATGGGCAAATACGGTCTCGG-CTTCAAATGGGCCC-CAGAATTTCCATGGATGCTTCCGAA
    SARS 265-410    (1) ATGGAGAGCCTTGTTCTTGGTGTCAACGAGAAAACACACGTCCAACTCAGTTTGCCTG--TCCTTCAGGT
                        71                                                                 140
    BCoV 211-350   (69) CGCAGAGGAGAAGTTGGATAACCCTAGTAGTTCAGAGGTGGA-----TATAGTATGCTCCACCACTGCGC
HECV4408 211-350   (69) CGCAGAGGAGAAGTTGGACAACCCTAGTAGTTCAGAGGTGGA-----TATAGTATGCTCCACCACTGCGC
HCoV-OC43 211-350   (69) CGCAGAGGAGAAGTTGGATAACCCTAGTAGTTCAGAGGTGGA-----TATGATTTGCTCCACCACTGCGC
    PHEV 211-450   (69) CGCAGAGGAGAAGTTGGATAACCCTAGTAGTTCAGAGGTGGA-----TATAGTTTGCTCCACCACTGCGC
 MHV A59 211-350   (69) CGCATCGGAGAAGTTGGGTAACCCTGAGAGGTCAGAGGAGGA-----TGGGTTTTGCCCCTCTGCTGCGC
    SARS 265-410   (69) TAGAGACGTGCTAGTGCGTGGCTTCGGGGACTCTGTGGAAGAGGCCCTATCGGAGGCACGTGAACACCTC
                        141 
    BCoV 211-350  (134) AAAAGCT- 
HECV4408 211-350  (134) AAAAGCT- 
HCoV-OC43 211-350  (134) AAAAGCT- 
    PHEV 211-450  (134) AAAAGCT- 
 MHV A59 211-350  (134) AAGAACC- 
    SARS 265-410  (139) AAAAATGG 
                         1                                                                   70
     FCoV 312-450    (1) ------------------------------ATGAGTTCCAAACAATTTAAGATCCTCGTTAATGAGGACT
     TGEV 315-450    (1) ------------------------------ATGAGTTCCAAACAATTCAAGATCCTTGTTAATGAGGACT
     PEDV 297-450    (1) ------------------------------ATGGCTAGCAACCATGTCACATTGGCGTTTGCCAATGATG
HCoV 229E 293-450    (1) ------------------------------ATGGCCTGCAACCGTGTGACACTTGCCGTAGCAAGTGATT
     SARS 265-450    (1) ATGGAGAGCCTTGTTCTTGGTGTCAACGAGAAAACACACGTCCAACTCAGTTTGCCTGTCCTTCAGGTTA
                         71                                                                140
     FCoV 312-450   (41) ACCAAGTCAACGTTCCTAGCCTTC------CTTTCCGTGACGCACTGCAGGAAATTAAGTACTGCTACCG
     TGEV 315-450   (41) ATCAAGTCAACGTGCCTAGTCTTC------CTATTCGTGACGTGTTACAGGAAATTAAGTACTGCTACCG
     PEDV 297-450   (41) CAGAAATTTCGGCTTTTGGCTTTTG---CACTGCTAGTGAAGCCGT-CTCATACTATTCTGAGGCCGCCG
HCoV 229E 293-450   (41) CTGAAATTTCTGCAAATGGCTGTTC---TACTATTGCGCAAGCCGT-CCGCCGTTATAGCGAGGCCGCTA
     SARS 265-450   (71) GAGACGTGCTAGTGCGTGGCTTCGGGGACTCTGTGGAAGAGGCCCTATCGGAGGCACGTGAACACCTCAA
                         141                                               193 
     FCoV 312-450  (105) TAACGGTTTTGATGGCTATGTCTTCGTGCCTGAAT------------------ 
     TGEV 315-450  (105) TAATGGATTTGAGGGCTATGTTTTCGTACCAG--------------------- 
     PEDV 297-450  (107) CTAGTGGATTTATGCA-ATGCCGTTTTGTGTCCCTCGATCTCGCTGACA---- 
HCoV 229E 293-450  (107) GCAATGGTTTTAGGGC-ATGCCGATTTGTTTCATTAGATTTGCAGGATTGCAT 
     SARS 265-450  (141) AAATGGCACTTGTGGTCTAGTAGAGCTGGAAAAAGGCGTACTGCCC------- 
 131
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure A3-2.  Group 1 and Group 2 nsp 1 Amino Acid Alignment. 
                                  1                                                                   70
          BCoV U00735 nsp1    (1) MSKINKYGLELHWAPEFPWMFEDAEEKLDNPSSSEVDIVCSTTAQKLETGGICPENHVMVDCRRLLKQEC
         MHV AY700211 nsp1    (1) MAKMGKYGLGFKWAPEFPWMLPNASEKLGNPERSEEDGFCPSAAQEPKVKGKTLVNHVRVNCSRLPALEC
        SARS AY291315 nsp1    (1) ------------------------------------------------------MESLVLGVNEKTHVQL
    Bat-SARS DQ022305 nsp1    (1) ------------------------------------------------------MESLVLGVNEKTHVQL
BatCoV HKU4-1 EF065505 nsp1    (1) ---------------------------------------MLSKASVTTQGARGKYRAELYNEKRSDHVAC
BatCoV HKU9-1 EF065513 nsp1    (1) ---------------------------------------------------------------------M
       FCoV NC_007025 nsp1    (1) ----------------------------------------------------------------------
       TGEV NC_002306 nsp1    (1) ----------------------------------------------------------------------
   HCoV 229E AF304460 nsp1    (1) ----------------------------------------------------------------------
       PEDV NC_003436 nsp1    (1) ----------------------------------------------------------------------
                                  71                                                                 140
          BCoV U00735 nsp1   (71) CVQSSLIREIVMNTRPYDLEVLLQDALQSREAVLVTPPLGMSLEACYVRGCNPNGWTMGLFRRRSVCNTG
         MHV AY700211 nsp1   (71) CVQSAIIRDIFVDEDPQKVEASTMMALQFGSAVLVKPSKRLSIQAWTNLGVLPKTAAMGLFKRVCLCNTR
        SARS AY291315 nsp1   (17) SLPVLQVRDVLVRGFGDSVEEALSEAREH-------LKNGTCGLVELEKGVLPQLEQPYVFIKR----SD
    Bat-SARS DQ022305 nsp1   (17) SLPVLQVRDVLVRGFGDSVEEALSEAREH-------LKNGTCGLVELEKGVLPQLEQPYVFIKR----SD
BatCoV HKU4-1 EF065505 nsp1   (32) TVPLCDTDDMACKLTPWFEDGETAFNQVSSILKEKGKILFVPMHMQRAMKFLPGPRVYLVERLTGGMLSK
BatCoV HKU9-1 EF065513 nsp1    (2) VVTTLKWCDPFANPNVTGWDIPIEEALEYAKQQLRTPEPQLVFVPYYLSHAPGISGDRVVITDS----IW
       FCoV NC_007025 nsp1    (1) ------------------MSSKQFKILVNEDYQVNVPSLPFRDALQEIKYCYRNGFDGYVFVPEYRRDLV
       TGEV NC_002306 nsp1    (1) ------------------MSSKQFKILVNEDYQVNVPSLPIRDVLQEIKYCYRNGFEGYVFVPEYCRDLV
   HCoV 229E AF304460 nsp1    (1) -----------------MACNRVTLAVASDSEISANGCSTIAQAVRRYSEAASNGFRACRFVSLDLQDCI
       PEDV NC_003436 nsp1    (1) -----------------MASNHVTLAFANDAEISAFGFCTASEAVSYYSEAAASGFMQCRFVSLDLADTV
                                  141                                                                210
          BCoV U00735 nsp1  (141) RCAVNKHVAYQLYMIDPAGVCFGAGQFVGWVIPLAFMPVQSRKFIVPWVMYLRKCGEKGAYNKDHKR-GG
         MHV AY700211 nsp1  (141) ECSCDAHVAFHLFTVQPDGVCLGNGRFIGWFVPVTAIPEYAKQWLQPWSILLRKGGNKGSVTSGHFRRAV
        SARS AY291315 nsp1   (76) ALSTNHGHKVVELVAEMDGIQYGRS----GITLGVLVPHVGETPIAYRNVLLRKNGNKGAGGHSYGIDLK
    Bat-SARS DQ022305 nsp1   (76) ALSTNHGHKVVELVAELDGIQFGRS----GITLGVLVPHVGETPIAYRNVLLRKNGNKGAGGHSFGIDLK
BatCoV HKU4-1 EF065505 nsp1  (102) HFLVNQLAYKDQVGAAMMRTTLNAK------PLGMFFPYDSSLETGEYTFLLRKNGLGGQLFRERPW---
BatCoV HKU9-1 EF065513 nsp1   (68) YATNFGWQPIRELAMDKDGVRYGRG----GTHGVLLPMQDPSFIMGDIDIQIRKYGIGANSPPDVLPLWD
       FCoV NC_007025 nsp1   (53) DCNRKDHYVIGVLGNGISDLKPVLLTEPSVMLQGFIVRANCNGVLEDFDLKFARTGNG------------
       TGEV NC_002306 nsp1   (53) DCDRKDHYVIGVLGNGVSDLKPVLLTEPSVMLQGFIVRANCNGVLEDFDLKIARTG--------------
   HCoV 229E AF304460 nsp1   (54) VGIADDTYVMGLHGNQTLFCNIMKFSDRPFMLHGWLVFSNSNYLLEEFDVVFGKRG--------------
       PEDV NC_003436 nsp1   (54) EGLLPEDYVMVVIGTTKLSAYVDTFGSRPRNICGWLLFSNCNYFLEELELTFGRRGG-------------
                                  211                                      254 
          BCoV U00735 nsp1  (210) FEHVYNFKVEDAYDLVHDEPKGKFSKKAYALIRGYRG------- 
         MHV AY700211 nsp1  (211) TMPVYDFNVEDACEEVHLNPKGKYSCKAYALLKGYRG------- 
        SARS AY291315 nsp1  (142) SYDLGDELGTDPIEDYEQNWNTKHGSGALRELTRELNGG----- 
    Bat-SARS DQ022305 nsp1  (142) SYDLGDELGTDPIEDYEQNWNTKHGSGALRELTRELNGG----- 
BatCoV HKU4-1 EF065505 nsp1  (163) --DRKETPYVEILDDLEADPTGKYSQNLLKKLIGG--------- 
BatCoV HKU9-1 EF065513 nsp1  (134) GFSDPGPDVGPYLDFPDNCCPTKPKAKRGGDVYLSDQYGFDNNG 
       FCoV NC_007025 nsp1  (111) -------------------------------------------- 
       TGEV NC_002306 nsp1  (109) -------------------------------------------- 
   HCoV 229E AF304460 nsp1  (110) -------------------------------------------- 
       PEDV NC_003436 nsp1  (111) -------------------------------------------- 
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BCoV nsp 1 Bioinformatics- PSI-BLAST Results 
1.  PSI-BLAST with BCoV p28 amino acids 37-76 
The first non-CoV sequence was selected after psi-blast 2. 
 
Physcomitrella patens subsp. patens  (Genbank #EDQ51842):   E-value:  5e-10 
 
BCoV    37  DIVCSTTAQKLETGGICPENHVMVDCRRLLKQECCVQSSL  76 
            D  C +  QK+     C   H   +C  L +Q+  +QS++ 
Sbjct  153  DTECPSPHQKMGQCMYCGGKHNTANCWYLPRQKTMIQSTV  192 
 
 
Sequence used for SMART domain search 
  1 MFVKESQPVT VAASLVRAKV WEECHYDQLL MVGTTMIPSI GNQVPMTNTM IESYPRMIAP 
 61 SMGNPNSQGV VNATPLQAIP PVATYPSPMA YRQREVPMNA TINNSNEALL LNLTKKMEEL 
121 AMHMTKDKEK RHKPSNMRPN VWCNNCKGQG HFDTECPSPH QKMGQCMYCG GKHNTANCWY 
181 LPRQKTMIQS TVWDVNQVQT GNMGGWNGNR NNRVNRGFGN FQNPNYNQPY GTNMQNGITG 
241 TLGGSDSRSI DKKSAKRQRI NSNIGEIDTS PGQQTNTKIC SIIGRSVTVT TQFDQYIGTS 
301 INFTSTNITP IRWTIASVKG SNFQGAVTTK NRGSTNS 
 
 
SMART Results 
Name Aa *E-Value Description 
Pfam: Znf nanos 112 159 5.60e+00 Zinc Finger; RNA-binding 
Pfam: DNAJ CXXCXGXG 111 186 9.70e+00 Zn dependent Cys rich domain 
Pfam:zf-CXXC 135 166 9.00e+00 DNA binding zinc finger  
**ZnF-C2HC 153 192 2.61e+02 Zinc finger; RNA/ssDNA binding  
ZnF-AN1 156 183 9.28e+02 Zinc finger; protein binding 
DNA Binding Motif 137 177 1.00e+03 DNA binding domain 
eIF2B-5  55 172 3.25e+03 Contains putative C4 Zn finger 
*  E-value=score representing the probability that two sequences are matched by chance.  A lower number indicates 
a lower probability. 
** Domain identified using only amino acids 153-192 
 
This hit identifies multiple types of Zinc fingers and DNA binding domains similar to those 
predicted to exist in BCoV. 
 
 
 
2.  PSI-BLAST with BCoV p28 amino acids 100-160 
The first non- CoV sequence was selected after psi-blast 2. 
 
Burkholderia pseudomallei  (Genbank #ZP_02403227)  E-value:  4e-10 
 
BCoV  102  AVLVTPPLGMSLEACYVRGCNPNGWTMGLFRRRSVCNTGR  141 
           A ++TPP    +   Y     P G   G   R + C +G+ 
Sbjct  61  ATVLTPPKRFDIGKWYNFAVMPGGKAEGPIYRGTFCISGK  100 
 
 
Sequence used for SMART domain search 
  1 MYSDERRRAS RNAARFHWRE PSHGASQSRC HLLASRSVGQ RSPVYLKRGD CIVYGQSIPG 
 61 ATVLTPPKRF DIGKWYNFAV MPGGKAEGPI YRGTFCISGK QGDSGRVVLR SENKDACSSG 
121 R 
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SMART Results 
Name Aa *E-Value Description 
KAZAL type protease inhibitors  23 51 1.37e+03 Serine protease inhibitor 
*  E-value=score representing the probability that two sequences are matched by chance.  A lower number indicates 
a lower probability. 
 
 
This hit identifies a putative protein binding domain found in serine protease inhibitors. Although 
this particular domain was not predicted in BCoV, two different potential inhibitor domains were 
predicted.  
 
 
 
3.  PSI-BLAST with BCoV p28 amino acids 94-189 
The first non- CoV sequence was selected after psi-blast 1 
 
Polaribacter dokdonensis  (Genbank #EAQ41748):  E-value: 5e-21 
 
BCoV  94    QDALQSREAVLVTPPLGMSLEACYVRGCNPNGWTMGLFRRRSVCNTGRCAVNKHVAYQLY  153 
            QD  + + A ++     + L   +V   N   +    + R+ +       +N  V Y  Y 
Sbjct  8    QDVKEGKLAAIICHFWIVGLVIGFVMNLNKKNYFTSFYLRQMIGMNLAQFLNGVVVYA-Y  66 
 
BCoV  154   MIDPAGVCFGAGQFVGWVIPLAFMPVQSRKFIVPWV  189 
            + D AG   G   FVGW+I L F  ++  + +VP+V 
Sbjct  67   LGDTAGWIVGILLFVGWLISL-FGAIKGEEKLVPYV  101 
 
 
Sequence used for SMART domain search 
 1 MEVINNEQDV KEGKLAAIIC HFWIVGLVIG FVMNLNKKNY FTSFYLRQMI GMNLAQFLNG 
61 VVVYAYLGDT AGWIVGILLF VGWLISLFGA IKGEEKLVPY VGEYFQDWFN QI 
 
 
SMART Results 
Name Aa *E-Value Description 
Transmembrane 72 91 - Confidently predicted domain 
*  E-value=score representing the probability that two sequences are matched by chance.  A lower number indicates 
a lower probability. 
 
This hit confidently predicts a transmembrane domain within the region aligned with the 
sequence predicted to be a transmembrane domain in BCoV. 
 
 
4.  PSI-BLAST with BCoV p28 amino acids 90-246 
No non-coronavirus sequences were identified. 
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TMpred Plot for BCoV and MHV p28 Transmembrane Domains 
 
BCoV:  STRONGLY preferred model: N-terminus inside 
 
Amino Acid Length Score Orientation 
158 179 22 1625 i-o 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MHV:  STRONGLY preferred model: N-terminus inside 
 
Amino Acid Length Score Orientation 
160 181 22 575 i-o 
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